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Inflammatory bowel disease (IBD) is a chronic, relapsing inflammatory disorder of the 
gastrointestinal tract. Cytokines have a critical role in the pathogenesis of IBD, in which they 
control multiple aspects of the inflammatory response. One such cytokine, Interleukin (IL-36) is 
overexpressed in both experimental and human IBD and may play both pathogenic and protective 
roles, depending on the context. The IL-36 signaling pathway induces IL-22, a cytokine that is 
critical in repair and regeneration of the gut epithelium during inflammation. However, the 
mechanism by which IL-36 induces IL-22 and promotes barrier repair is incompletely understood.  
We observed a cytokine network, in which, IL-36γ/IL-36R signaling is an important 
upstream driver of IL-22 and antimicrobial peptide (AMP) production to protect the host against 
acute intestinal damage. We have shown that IL-36γ is a potent inducer of IL-23. IL-36γ–induced 
IL-23 requires Notch2-dependent dendritic cells (DCs). The intracellular signaling cascade linking 
IL-36 receptor (IL-36R) to IL-23 production by DCs involved MyD88 and the NF-κB subunits. 
Consistent with in vitro observations, IL-36R-/- mice exhibited dramatically reduced IL-23, IL-22, 
and AMP levels, and consequently failed to recover from acute intestinal damage. Interestingly, 
impaired recovery of mice deficient in IL-36R was rescued by treatment with exogenous IL-23. 
We also found that IL-36R-/- mice are defective of host protection during enteropathogenic 
bacterial infection. The IL-36 signaling cascade is essential in both early and late phases of immune 
defense against C. rodentium infection. During the early stage of infection, IL-36 induced the 
production of IL-22 by innate lymphoid cells 3 (ILC3s) via IL-23; and during the late phase, IL-
36 stimulated the production of IL-22 from T-cells via IL-6. Intriguingly, in the experimental 
chronic colitis, IL-36R-/- mice display reduced disease severity and are associated with decrease 
production of inflammatory cytokines and enhances expression of Foxp3 regulatory T cells. 
Collectively, these findings highlight context-dependent, protective and pathogenic contribution 
of the IL-36R signaling pathway and the potential for optimally manipulating this pathway for 
better treatment of intestinal inflammation. 
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1 CHAPER 1: BRIEF LITERATURE REVIEW  
1.1 Inflammatory bowel disease (IBD) 
Inflammatory bowel diseases (IBD), comprised of ulcerative colitis (UC) and Crohn’s 
disease, are chronic relapsing disorder affecting the gastrointestinal tract. Affecting approximately 
1.5 million Americans, two million European and several hundred thousand more world-wide, 
IBD are global disorders with high rates of occurrence in developed countries [1-5]. However, 
since 1990 the rate of incidence of IBD in Western countries has started to decline and stabilize, 
while the incidence rate in newly industrialized countries in South America, Africa, and Asia is 
accelerating [6].  
 Both UC and Crohn’s disease are typified by non-infectious chronic inflammation of the 
digestive tract. The inflammation in UC is characterized by continuous inflammation in the large 
intestine and limited to the mucosal and submucosal layers. In contrast, irregular inflammation 
involving all segments of the gastrointestinal tract that occurs anywhere from the oral cavity to the 
anus is typically an indicator of CD [2, 7, 8]. The symptoms of IBD can range from mild to severe, 
depending on the stage of the disease and the portion of the gastrointestinal tract affected. 
Symptoms often include abdominal pain, abnormal frequency of bowel movement, diarrhea, fever, 
weight loss, and loss of appetite [9, 10]. Although IBD does not affect the patients’ life expectancy, 
it has a substantial impact on their quality of life with IBD patients usually experiencing fatigue 
during remission and flareup [10]. Moreover, the destructive nature of the disease can lead to 
complications such as stenoses, abscesses, fistulas, extraintestinal manifestations, and colitis-
associated cancer often observed in IBD patients [2, 3, 7, 8]. 
2 
1.1.1 Pathogenesis of IBD 
The etiology of IBD remains unclear; however, it is hypothesized that these disorders  are 
the result of irregular immune responses to microbiota in genetically vulnerable individuals [2, 8]. 
Studies have shown that environment and genetic factors play a critical role. Gene polymorphisms 
in loci coding molecules that affect chemokines, cytokine signaling, antimicrobial peptides, and 
molecules involved in the sensing of immune cells have been revealed to increase the prospect of 
developing IBD [7, 11, 12]. In addition, environmental factors such as, stress, smoking, and 
prescribed antibiotics all increase the risk of IBD [13-15]. However, none of the predisposing 
components mentioned above can act alone to trigger IBD, instead the combination of genetics, 
environmental factors, and host-microbe interaction appears to prompt IBD-initiating events. This 
leads to impaired intestinal barrier function and eventually results in the translocation of 
microorganisms from the lumen to the bowel wall.  Consequently, innate immune cells respond to 
foreign microorganisms and lead to the activation of immune cells and the production of 
cytokines/chemokines. That process in turn impair gut homeostasis and recruit addition immune 
cells and causes the activation of adaptive immunity [11-13, 16-20]. Mediators including cytokines 
and chemokines produce by activated immune cells can then induce epithelial damage, impairment 
of barrier function and dysbiosis and perpetuate gut inflammation [2, 8, 21].  
1.1.2 Cytokines in IBD 
Cytokine responses orchestrate the initiation, progression, and resolution of the diseases 
and are thought to be critical elements in IBD [2, 8]. Upon secretion, these cytokines trigger the 
differentiation of mucosal naïve T-cells to effector T cells or regulatory T-cell. Different lineages 
of effector T-cells are crucial for host protection against foreign microbes. However, the imbalance 
of effector T cells and regulatory T cells can result in chronic IBD. As a result, the immune system 
3 
has several mechanisms to control these effector T cells, of which the CD4+ regulatory T-cells 
(Treg) are the most important. This balance between effectors and T-reg is essential for the 
safeguarding of intestinal homeostasis. Previous studies have indicated that IBD patients can either 
exhibit TH1 mediated immune response, which is characterized by up-regulation of TNF, IFN-γ, 
IL-12 mediated immune response or characterized by increase production of TH2 related cytokines 
(IL-4, IL-13) [22-25]. Figures below adapted from Neurath, M. et al., Cytokines in inflammatory 










Figure 1.1 Key cytokine in IBDs. From Neurath, M. Cytokines in inflammatory bowel disease. Nat 
Rev Immunol 14, 329–342 (2014) 
1.2 IL-36 Cytokines 
The IL-36 cytokines were discovered almost twenty-years ago through genome screening 
and identified due to their structural homolog to IL-1 [26, 30, 31]. IL-36 cytokine subfamily 
comprises of four members and originally named as IL-1F6, IL1F8, IL1F9 and IL-1F5 for belong 
to IL-1 superfamily, but later re-named to IL-36, IL-36, IL-36 and IL-36Ra. The encoding 
4 
gene for IL-36 was found to be clustered on chromosome two and subsequently cloned in 2001 
[32, 33]. While IL-36, IL-36 and IL-36 function as IL-36 receptor agonists, IL-36Ra (IL-36 
receptor antagonist) prevents the activation of IL-36R signaling. All IL-36 cytokines ligands bind 
to the IL-36 receptor complex (IL-36R), which is comprised of the IL1-R-related protein 2 (IL-
1RL2) and a co-receptor subunit IL-1 receptor accessory protein (IL1RAcP) [34, 35]. Through a 
combination of in vitro/in vivo characterizations and structural studies, the functions of IL-36 has 
begun to unveil over the last 20 years. Depending on the location of expression, phases, and context 
of the diseases, IL-36 cytokines can either favor inflammation or promote the resolution of 
inflammation. IL-36 was best comprehensively studied and explored in the context of skin 
inflammation, such as psoriasis [35, 36]. Over the past decades, the pathological and protective 
effects of IL-36 cytokines have been expanded to a range of inflammatory diseases including 
systemic lupus erythematosus, psoriatic, inflammatory bowel diseases [37-47]. In addition, IL-36 
cytokines have also been found to respond to inflammatory signals induced bacterial and viruses, 
indicating their role in anti-bacterial and anti-virus infection [34, 35, 48-53]. 
1.2.1 Secretion of IL-36 
Expression of IL-36 cytokines is observed at low level across different organs including 
skin, intestines, lung, and brain. During inflammation IL-36 mainly expressed by keratinocytes, 
epithelial cells, inflammatory monocytes/macrophages. In vitro studies demonstrated that Ly6C+ 
monocytes or bone marrow derived macrophages responses to toll-like receptor ligands including 
LPS, flagellin, CpG, and Poly I:C or inflammatory cytokines (IL-1, IL-18) to induces robust 
secretion of IL-36γ [32, 34, 48]. In the skin, epidermal growth factors (EGFs) have been identified 
as triggers for IL-36 cytokine production in the skin during psoriasis. In several models of asthma, 
lung epithelial cells have been reported to produce IL-36 agonist ligands in responses to 
5 
Rhinovirus stimulation. T lymphocytes have been reported to express the IL-36 agonists under 
influences of fibroblast growth factors (FGFs). In addition, IL-36α is upregulated in synovium-
infiltrated plasma cells of rheumatoid arthritis patients. IL-36 cytokines are also found to be 
elevated in the lung in response to various bacterial/ viral infections [35, 37, 38, 48, 52, 53]. In the 
intestine, IL-36α and IL-36γ were highly upregulated in multiple models of murine intestinal 
inflammation as well as in IBDs patients [43, 45-47, 54-56]. In cultured human KCs, IL-36 
cytokines can also induce the expression of themselves in an autocrine loop, emphasizing its potent 
proinflammatory functions [57]. Like its ligands, the IL-36R complex is also widely expressed at 
low level and does not seem to be upregulated unless there are pathological conditions present. 
Collectively, these finding suggest that IL-36 cytokines are produced in response to the diseases 
in a stimuli-dependent fashion; however, the regulatory mechanism triggering the production of 
IL-36 cytokines remains unknown.  
The secretion mechanisms of IL-36 cytokines are not well-known. All IL-36 agonist ligands 
do have signal sequences or caspases cleavage site; hence, they are release from cells by an 
endoplasmic reticulum and Golgi independent secretion pathway. Studies established that IL-36α 
and IL-36γ produced by macrophages are accumulated intracellularly and is release in response to 
ATP stimulation. Kovach et al., demonstrated that IL-36γ secreted by lung alveolar macrophages 
within microparticle in responses to bacterial infection [50, 58]. In addition, a recent study showed 
influenza virus induced capase-1 activation and led to the induce of IL-36α, however, caspase-3 
and caspase-7 are required for alveolar epithelial cells to release IL-36α [51, 53, 59-61]. 
1.2.2 Processing of IL-36 
Similar with other cytokines in IL-1 superfamily, all IL-36 ligands are secreted in inactive 
forms (pro-IL-36) and have little or no bioactivity. This low activity could be ascribed to the 
6 
absence of proteolytic processing that produces the active forms. All IL-36 agonists must be 
undergoing N-terminal cleave process by specific proteases to become activates their full 
biological potentials. Upon cleaved of nine amino acids in the N-terminal portion from the A-X-
Asp motif, IL-36 agonists greatly increase their affinity to bind to IL-36R complex [62]. 
Neutrophils proteases have been recognized as the main regulators of all the IL-36 family. 
Neutrophil Elastase (NE) is the enzyme responsible for enhancing IL-36Ra activity. Neutrophil-
derived proteases, cathepsin G, and elastase activate IL-36α; cathepsin G activates IL-36 while 
IL-36γ is activate by proteinase-3 and proteases elastase (Figure 1.1) [34, 59, 63, 64].  
1.2.3 IL-36 Signaling 
IL-36 ligands and IL-36R are expressed in wide range to tissues including gut, skin, lung, 
renal and cervical tissue. Once secretion, all IL-36 agonists ligands first bind to IL-1-R-relataed 
protein 2 (IL-1RL2), resulted in the recruitment of IL-1 receptor accessory protein (IL1RAcP) to 
form a functional IL-36R complex. Upon interacting with their receptor, IL-36 agonist triggers 
intracellular cascades leading to the activation of mitogen-activated protein kinase and nuclear 
factor kappa B (NFB) to induces various immune response [54, 56, 62]. IL-36Ra and IL-38 acts 
as an antagonist as they bind to IL1RL2 and inhibiting the recruitment of IL-1RAcP and prevent 
the creation of a heterodimeric IL-36R complex (Figure 1.1) [34, 65]. 
1.2.4 IL-36 cytokines and their effects on immune cells 
IL-36 cytokines play a substantial role in shaping host immunity by exerting their influence 
on both the innate and adaptive arms of the immune system. Studies have shown that IL-36 has 
effect on dendritic cells, macrophages, and fibroblasts. Both murine bone marrow-derived 
dendritic cells (BMDCs) and human monocytes derived dendritic cells (MDCs) express a higher 
level of IL-36R and response to the stimulation with IL-36 ligands by producing a wide range of 
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pro-inflammatory cytokines including IL-2, IL-23, IL-6, IL-12, GM-CSF, and TNF-. These 
cytokines then facilitate the differentiation of naïve CD4+ T cells into TH1, TH17/TH22 effector T 
cells. Furthermore, IL-36 can also govern the recruitment of innate immune cells by inducing the 
production of chemo-attractants including CXCL1, CXCL2, CXCL3, and CXCL5 (Figure 1.1) 
[36, 37, 40, 48, 66, 67]. 
 
 






2 CHAPTER 2: A CYTOKINE NETWORK INVOLVING IL-36 IL-23, AND IL-22 
PROMOTES ANTIMICROBIAL DEFENSE AND RECOVERY FROM 
INTESTINAL BARRIER DAMAGE 
Vu L. Ngo, Hirohito Abo, Estera Maxim, Akihito Harusato, Duke Geem, Oscar Medina-
Contreras, Didier Merlin, Andrew T. Gewirtz, Asma Nusrat, and Timothy L. Denning 
2.1 Abstract 
The gut epithelium acts to separate host immune cells from unrestricted interactions with the 
microbiota and other environmental stimuli. In response to epithelial damage or dysfunction, 
immune cells are activated to produce interleukin (IL)-22, which is involved in repair and 
protection of barrier surfaces. However, the specific pathways leading to IL-22 and associated 
anti-microbial peptide (AMP) production in response to intestinal tissue damage remain 
incompletely understood. Here we define a critical IL-36/IL-23/IL-22 cytokine network that is 
instrumental for AMP production and host defense. Using a murine model of intestinal damage 
and repair, we show that IL-36 is a potent inducer of IL-23 both in vitro and in vivo. IL-36-
induced IL-23 was dependent upon Notch2-dependent (CD11b+CD103+) DCs, but not Batf3-
dependent (CD11b-CD103+) DCs or CSFR1-dependent macrophages. The intracellular signaling 
cascade linking IL-36R to IL-23 production by DCs involved MyD88 and the NF-kB subunits c-
Rel and p50. Consistent with in vitro observations, IL-36R- and IL-36-deficient mice exhibited 
dramatically reduced IL-23, IL-22 and AMP levels and consequently failed to recover from acute 
intestinal damage. Interestingly, impaired recovery of mice deficient in IL-36R or IL-36 could be 
rescued by treatment with exogenous IL-23. This recovery was accompanied by a restoration of 
IL-22 and AMP expression in the colon. Collectively, these data define a cytokine network 
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involving IL-36, IL-23, and IL-22, that is activated in response to intestinal barrier damage and 
involved in providing critical host defense.  
2.2 Significance statement 
Cytokines are produced in response to microbial threat and aid in the recruitment and 
activation of immune cells in order to protect the host. Using complementary in vitro and in vivo 
approaches, we have defined a cytokine network involving IL-36, IL-23, and IL-22 that is induced 
following intestinal damage and critical for antimicrobial activity, tissue repair and host survival. 
Our data identify IL-36/IL-36R signaling as a central upstream driver of the IL-23/IL-22/AMP 
pathway during intestinal injury and advance the concept that IL-36 and IL-23 are fundamentally 
linked to repair of acute barrier damage. These findings provide new mechanistic insight into how 
the host commandeers pro-inflammatory cytokines for tissue repair and highlights the potential for 
manipulating the IL-36/IL-23/IL-22/AMP network in treating acute intestinal damage.  
2.3 Introduction 
At mucosal surfaces, particularly the intestine, epithelial cells form a physical and functional 
barrier that protects the host from the unrestricted barrage of microbial and environmental stimuli. 
Compromises in the epithelial barrier due to damage or dysfunction can result in activation of 
underlying immune cells. Once activated, innate and adaptive immune cells display enhanced anti-
microbial activity and promote epithelial proliferation, repair of the damaged barrier, and 
resolution of inflammation [68]. However, if the insult persists, or if repair processes are 
ineffective, chronic intestinal inflammation as seen in human inflammatory bowel disease (IBD) 
may ensue [69]. Therefore, delineating the specific mechanisms involved in efficient tissue repair 
processes in the damaged intestine may provide insight into therapeutic strategies for the treatment 
of these inflammatory conditions.  
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Interleukin (IL)-22 is a key cytokine that links intestinal immune activation to epithelial 
repair and barrier protection following damage [68, 70]. IL-22 is expressed by numerous immune 
cells including type 3 innate lymphoid cells (ILC3), natural killer (NK) cells, neutrophils, and 
Th17 and Th22 cells [71]. Intestinal epithelial cells express the IL-22R complex and binding of 
IL-22 results in the induction of mucins, antimicrobial peptides, and anti-apoptotic pathways that 
collectively aid in limiting bacterial encroachment while promoting epithelial proliferation, wound 
healing and repair [72]. Mice that lack the ability to produce IL-22 following treatment with 
dextran sodium sulfate (DSS) or Citrobacter rodentium are grossly unable to repair barrier damage 
or control pathogenic bacterial expansion [73-75]. These data suggest that IL-22 plays a non-
redundant function in mucosal barrier defense [76, 77].  
Investigations into how IL-22 is regulated have led to the identification of IL-23 as one of 
the most potent inducers of this cytokine. Systemic administration of bacterial flagellin was shown 
to rapidly induce IL-23 production by intestinal TLR5 expressing CD103+CD11b+ dendritic cells 
(DCs) and subsequent IL-22 expression [78].  Additionally, stimulation of intestinal ILC3s, NK 
cells, neutrophils and Th17 cells with IL-23 potently induces IL-22 production [71].  Similarly, 
loss of IL-23 signaling in vivo during DSS–induced colitis completely abrogates colonic IL-22 
expression and results in exacerbated disease [75]. Furthermore, IL-23p19-deficient mice fail to 
produce IL-22, which leads to overgrowth of segmented filamentous bacteria (SFB) [79]. 
Collectively, these studies demonstrate an important role for the IL-23/IL-22 axis in barrier 
protection and control of bacteria, yet the upstream regulators of this critical pathway are 
incompletely undefined.     
Among the many immunological factors produced in response to intestinal damage, IL-1 
superfamily cytokines appear to play a major role in the inflammatory program [80]. IL-1, IL-
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18, and IL-33 are all induced during experimental colitis and are believed to contribute to the 
pathogenesis of IBD, but may also be involved in tissue protection [81-83]. Similarly, IL-36 
cytokines, the more recently described members of IL-1 superfamily, appear to potently induce 
inflammatory responses and regulate mucosal immunity [49, 84]. We and others have reported 
that IL-36 cytokines are expressed in the intestine during inflammation [43, 55, 85-88] in response 
to stimulation by the microbiota [55]. Once expressed, IL-36 ligands are involved in the activation 
of innate and adaptive immune cells and stromal cells that can exacerbate intestinal inflammation, 
and also play an instrumental role in resolution of intestinal damage [55, 85, 89, 90]. This bi-
functional effect of the IL-36/IL-36R axis during intestinal inflammation likely depends on the 
inducing stimuli, extent of tissue damage, and timing and chronicity of expression. In response to 
robust intestinal barrier destruction, IL-36R signals augment the inflammatory cascade early on, 
which appears linked to subsequent tissue protection and repair [55, 85]. However, the specific 
pathways via which IL-36R signaling controls host defense and barrier protection remain to be 
elucidated.   
In this report, we define a critical IL-36/IL-23/IL-22 cytokine network that is instrumental 
for AMP production and host defense following intestinal damage. Using a murine model of 
colonic damage and inflammation, we show that IL-36 is a potent inducer of IL-23 production 
both in vitro and in vivo. IL-36-induced IL-23 was highly dependent upon Notch2-dependent 
(CD11b+CD103+) DCs, but not CSFR1-dependent macrophages or Batf3-dependent (CD11b-
CD103+) DCs. The intracellular signaling cascade linking IL-36R signaling to IL-23 production 
from DCs involved MyD88 and the NF-kB subunits c-Rel and p50. Consistent with in vitro 
observations, IL-36R-deficient mice exhibited dramatically reduced IL-23 and IL-22/AMP levels 
and consequently mice failed to recover from acute intestinal damage. Interestingly, impaired 
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recovery of mice deficient in IL-36R or IL-36 could be completely rescued by treatment with 
exogenous IL-23. This recovery was accompanied by a restoration of IL-22 and AMP expression 
in the colon. Collectively, these data define a cytokine network involving IL-36, IL-23, and IL-
22, that is activated in response to intestinal barrier damage and involved in providing critical host 
defense.  
2.4 Material and methods 
2.4.1 Mice  
The following mice were obtained from Jackson Laboratories: Wild-type C57BL/6 (B6 
WT), B6.129S(C)-Batf3 tm1Kmm/J (batf3-/-), CD11c-cre (B6.Cg-Tg(Itgax-cre)1-1Reiz/J), 
Notch2f/f (B6.129S-Notch2tm3Grid/J), B6.129P-Nfkb1 tm1Bal/J (p50-/ -), and B6.129P2(SJL)-
Myd88 tm1.1Defr/J (myd88-/-). IL-36R-/- mice (Il1rl2-/-) on the C57BL/6 background (backcrossed 
>9 generations) were originally provided by Amgen.  To generate IL-36γ-/- (Il1f9-/-) mice, sperm 
from IL-36γ-/- mice was obtained from the KOMP repository (UC Davis) and heterozygous Il1f9+/- 
founder mice were generated by the Mouse Transgenic and Gene Targeting Core facility at Emory 
University. Il1f9+/- mice were subsequently bred to generate Il1f9-/- mice on the C57BL/6 
background (backcrossed >9 generations). Notch2cKO mice were generated as previously described 
[91].  
2.4.2 DSS model of colitis. 
Mice were treated with 2.5% - 3% (wt/vol) DSS (MP Biomedicals; molecular weight: 
36,000-50,000) in their drinking water for 5 days and then switched to regular drinking water. 
Mice were monitored daily for signs of diseases and DAI and histology scoring was performed as 
previously described [55]. 
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2.4.3 Colonic explants 
Colon tissue was harvested from mice, open longitudinally, and washed in phosphate 
buffered saline + Tween-20 (PBS-T). Biopsy punches (3mm; Integra Miltex, New York, NY, 
United States) were used to excise sections of the colon, which were placed in 96-well plates and 
cultured with RPMI-1640 supplemented with 10% fetal bovine serum and penicillin/streptomycin. 
Recombinant IL-23 (R&D system, Minneapolis, MN, United States) or recombinant IL-36 
((R&D system, Minneapolis, MN, United States) were added to each well at 20ng/mL and 
100ng/mL, respectively. For gene expression analysis, tissues were collected and processed for 
downstream applications 6 hours following stimulation. For protein analysis, supernatant from the 
tissues were collected 60 hours after stimulation.  
2.4.4 ELISA 
IL-22 and IL-23 secretion was measured in cell-free culture supernatants using IL-22 and 
IL-23 ELISA kits (R&D system, Minneapolis, MN, United States) according to the manufacturer’s 
protocols. 
2.4.5 In vivo administration of IL-23 
Recombinant mouse IL-23 was purchased from R&D Systems (Minneapolis, MN). Il1rl2-
/- and Il1f9-/- mice received either PBS or 0.25ug of IL-23 via i.p. injection at day 3, 4 and 5 of 
DSS treatment. 
2.4.6 Histology 
Colons were fixed in 10% formalin. Paraffin embedding, sectioning, Hematoxylin/Eosin 
staining, and slide scanning was performed at the University of Michigan Pathology Core.  
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2.4.7 Bone marrow-derived dendritic cells.  
Bone marrow-derived dendritic cells (BMDCs) were generated from 8-15 week-old B6 
WT, c-Rel-/- and p50-/- mice. BM cells were harvested from femurs, and the red blood cells were 
lysed by using red blood cell lysis buffer. BM cells were cultured for 10 days in RPMI-1640 
supplemented with 10% fetal bovine serum (FBS), penicillin/streptomycin, and 50M -
mercaptoethanol. 20ng/mL of recombinant murine granulocyte macrophage colony-stimulating 
factor (Peprotech, Rocky Hill, NJ, United States) was added to cell cultures every two days. After 
10 days of culture, the generated DCs were harvested. BMDCs (3x105 cell/well) were seeded in 
96-well plates and cultured ± IL-36 (100ng/mL) for 6 hours or 24 hours. For inhibition of NF-B 
components, BMDCs was pretreated with the c-Rel inhibitor IT-603 (Calibiochem, San Diego, 
CA, United States) or p50 inhibitor peptide or p65 inhibitor peptide (Novus biological, Littleton, 
CO, United States) for 1 hour ± IL-36. After 1 hour of pre-treatment, media containing inhibitors 
and IL-36 was replaced with new media and incubated for 6 hours to analyze gene expression or 
24 hours to analyze protein expression. 
2.4.8 Quantitative real-time PCR 
Total RNA was isolated from colon tissues of mice using the Qiagen RNeasy Mini Kit and 
QIAcube with on-column DNase digestion according to the manufacturer’s protocol. cDNA was 
generated using the Superscript First Strand Synthesis kit for RT-PCR and random hexamer 
primers (Invitrogen). Q-PCR was performed with SYBR Green using a StepOnePlus PCR system 
(Applied Biosystem) and gene expression was normalized to gapdh.  
2.4.9 Chromatin Immunoprecipitation (ChIP) assay 
BMDCs were cultured ± IL-36 (100ng/mL) for 8 hours. ChIP assays were performed 
using EZ-ChIP kit (EMD Millipore 17371) according to manufacturer’s protocol. Briefly, 
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chromatin was obtained from the cultured cells after fixation with 18.5% formaldehyde and 
fragmented by sonication.  One tenth of each fragmented chromatin sample was saved before 
immunoprecipitation for use as an input control. The remaining fragmented chromatin was 
immunoprecipitated with either control or anti-p50 (clone SC-8418) or anti-c-rel (clone sc-6955) 
antibodies (Santa Cruz Biotechnology). DNA recovered from the immunoprecipitation and input 
control were analyzed by qPCR. 
2.4.10 Quantitation of fecal bacteria abundance.  
Fecal samples were collected before DSS treatment and 6 days after beginning DSS 
treatment. All feces were stored at -80oC until DNA extraction. The total genomic DNA from each 
fecal sample was extracted using the QIAamp DNA stool minikit according to the manufacturer’s 
protocol. Samples were analyzed for bacterial gene expression using the qPCR. 
2.4.11 qPCR primer 

















































Fwd 5'-ACGGTACTTGAGGAGGA -3' 
Rev 5'-GAGCCGTAGCCTTTCACT -3' 
Helicobacter  





















2.4.12 Statistical analysis 
All statistical analyses were performed with GraphPad Prism software, version 7.0 
(Graphpad Software). ONE-way ANOVA and Tukey’s Multiple Comparison Test or Student’s t 
test were used to determine significance. *P < 0.05, **P < 0.01, ***P < 0.001; n.s.= not significant.  
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2.5 Results 
2.5.1 IL-36R-deficiency results in impaired IL-23 and IL-22 expression in the colons of 
DSS-treated mice.  
Recently, IL-36R signaling has been implicated in healing of mucosal damage [55, 85, 92] 
and our group demonstrated that IL-36R-deficient (Il1rl2-/-) mice have impaired IL-22 production 
and consequently fail to recover from acute intestinal damage. In order to begin exploring potential 
mechanisms of how IL-36R signaling induces IL-22 expression, we performed a PCR array on 
total colonic tissues isolated from Il1rl2+/+ and Il1rl2-/- mice at day 5 of DSS treatment. The array 
analysis revealed that the expression of IL-23 and IL-22 mRNA was ~9-fold and ~7-fold higher, 
respectively, in Il1rl2+/+ mice when compared to Il1rl2-/- mice (Figure 2.1A). Given that IL-23 is 
a potent inducer of IL-22 [71], we postulated that impaired IL-22 expression in Il1rl2-/- mice may 
be associated with  a lack of IL-23. To explore the link between IL-36R signaling, IL-23, and IL-
22, we first examined the expression of IL-23 and IL-22 in Il1rl2+/+ and Il1rl2-/- mice during the 
course of DSS treatment (5 days DSS followed by 2 days of regular water). Quantitative PCR and 
ELISA analysis of colonic tissue revealed that DSS-induced expression of IL-23 and IL-22 mRNA 
and protein was significantly higher in colonic tissue isolated from Il1rl2+/+ mice when compared 
to Il1rl2-/- mice (Figure 2.1 B-E). Additionally, following DSS treatment, the peak of IL-36 
expression preceded that of IL-23 and IL-22 at day 3, followed by robust IL-23 expression on day 
5 and IL-22 expression on day 7 (Figure 2.7 A). Collectively, these data suggest that signaling via 
IL-36R is involved in optimal IL-23 and IL-22 expression during DSS-induced damage.  
20 
2.5.2 IL-36-induced IL-22 production in colonic explants from DSS-treated mice is IL-23 
dependent. 
Next, we determined whether IL-23 is required for IL-36-induced IL-22 expression in 
colonic explants from DSS-treated mice. We focused our studies on IL-36 as it is the predominant 
IL-36 ligand produced in the colon of mice during DSS-induced damage [55]. Colonic explants 
isolated from healthy (non-DSS treated), wild type (WT) mice and stimulated with IL-36 in vitro 
showed no detectable increases in either IL-23 or IL-22. However, colonic explants isolated from 
DSS-treated mice on day 3, a time when endogenous IL-36 mRNA expression is highest (Figure 
2.7 A and [55]), responded to exogenous IL-36 stimulation by inducing IL-23 (~3-fold) and IL-
22 (~5-fold) compared to unstimulated controls (Figure 2.2 A and B). Of note, IL-36 and IL-36 
were also capable of inducing IL-23 and IL-22 (Figure 2.7 B and C). These data further correlated 
with a strong induction of IL-36R (Il1rl2) mRNA expression at day 3 following DSS treatment 
(Figure 2.7 D). Having established that IL-36 is an inducer of IL-23, we next assessed whether 
IL-36-induced IL-22 was IL-23-dependent. Indeed, antibody-mediated blockade of IL-23p19 
(p19) or IL-12/23p40 (p40) was able to significantly reduce the ability of IL-36 to induce IL-
22 in colonic explants from DSS-treated mice (Figure 2.2 C). Similarly, while colonic explants 
from DSS-treated IL-12/23p40-sufficient mice (Il12b+/+) produced high levels of IL-22 in 
response to IL-36 stimulation, explants obtained from DSS-treated IL-12/23p40-deficient mice 
(Il12b-/-) produced significantly less IL-22 under these conditions. This defect in IL-36-induced 
IL-22 production in Il12b-/- explant cultures was reversible by the addition of exogenous IL-23 
(Figure 2.2 D). These results highlight a functional IL-36/IL-23/IL-22 cytokine network in 
colonic tissue from DSS-treated mice.  
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2.5.3 Notch2-dependent DCs are required for IL-36-induced IL-23 and IL-22 expression 
and recovery from acute colonic damage. 
Having established IL-23 as a key intermediary between IL-36 and IL-22, we next 
examined whether specific antigen-presenting cell subsets may be involved in IL-23 induction in 
response to IL-36. Intestinal DCs are categorized into two main populations: Notch2-dependent 
DCs and Batf3-dependent DCs [91]. Within these subsets, CD103+CD11b+ DCs have been 
reported to accumulate in the intestines during DSS-induced colitis [93]. To determine if either of 
these DC subsets are involved in IL-36-induced IL-23 production, we used Notch2-floxed mice 
that had been crossed with CD11c-Cre mice to generate mice with a deletion of Notch2 in the DC 
lineage (Notch2cKO), as well as Batf3-deficient mice (batf3-/-). Initially, we examined the 
expression of IL-36R (Il1rl2) mRNA in colonic tissue isolated from these mice following 
treatment with DSS for 3 days. Consistent with Figure 2.7B, we found that Il1rl2 was strongly 
induced in the colons of DSS-treated WT (batf3+/+) mice, as well as in batf3-/- mice. Conversely, 
the induction of Il1rl2 was significantly reduced in the colons of DSS-treated Notch2cKO mice, 
when compared to control mice (Notchfl/fl) (Figure 2.3 A). Next, colonic explants from DSS-treated 
batf3-/- and Notch2cKO mice, and their respective controls, were stimulated in vitro with IL-36 and 
IL-23 as well as IL-22 expression was assessed by ELISA. While batf3-/- mice exhibited normal 
induction of IL-23 and IL-22 in response to IL-36, Notch2cKO mice completely failed to produce 
IL-23 and IL-22 in the presence of IL-36, when compared to when compared Notchfl/fl controls. 
Furthermore, the addition of exogenous IL-23 to Notch2cKO explant cultures was sufficient to 
restore IL-22 production in these cultures to normal levels (Figure 2.3 B and C). Thus, IL-36-
induced IL-23 appears to be dependent upon Notch2-dependent DCs in vitro. Of note, 
macrophages did not appear to play a significant role in IL-36-induced IL-23 expression during 
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DSS since treatment of mice with CSF-1R antibody to deplete macrophages [94] had no 
detectable effect on the ability of IL-36 to induce IL-23 or IL-22 in colonic explant cultures 
(Figure 2.8 A-C). 
To investigate whether Notch2-dependent DCs are also necessary for host recovery from 
DSS-induced intestinal damage in vivo, the disease activity index (DAI) of batf3+/+, batf3-/-, 
Notch2fl/fl, and Notch2cKO mice was compared following administration of DSS in the drinking 
water for 5 days followed by normal water thereafter. While batf3+/+, batf3-/-, and Notch2fl/fl mice 
were all able to recover normally from DSS-induced intestinal damage, Notch2cKO mice were 
defective in colonic repair and had higher DAI scores (Figure 2.3 D), shorter colon length (Figure 
2.3 E), and significantly reduced levels of IL-23 and IL-22 in colons directly ex vivo (Figure 2.3 F 
and G). Together, these data highlight Notch2-dependent DCs as a critical cellular source of IL-
23 in response to IL-36 stimulation.   
2.5.4 IL-36 induces IL-23 via signaling through MyD88, c-Rel and NF-Bp50.  
MyD88 is an adaptor protein known to induce signaling through Toll-like receptors (TLRs) 
as well as IL-1 family receptors. To begin to define the signaling cascade linking IL-36R signaling 
to IL-23 expression in DCs, we generated bone marrow-derived DCs (BMDCs) from WT 
(myd88+/+) and MyD88-deficient (myd88-/-) mice and cultured them in the absence or presence of 
IL-36. Upon stimulation of myd88+/+ BMDCs with IL-36, IL-23 was robustly expressed, while 
myd88-/- BMDCs completely failed to induce IL-23 protein secretion in response to IL-36 
stimulation (Figure 2.9).  
We next explored the involvement of the NF-kB pathway in IL-36-induced IL-23 
expression. Since previous studies have implicated c-Rel in the expression of IL-23p19 to form 
functional IL-23 [95], we investigated the effects of c-Rel deficiency on IL-36-induced IL-23 
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expression by using BMDC isolated from c-rel+/+ and c-rel-/- mice.  Following stimulation with 
IL-36 for 6 hours, we observed a strong induction of IL-23 from c-rel+/+ BMDCs, but no increase 
over baseline in c-rel-/- cultures (Figure 2.4 A). Similarly, treatment with the c-Rel inhibitor IT-
603 nearly completely abolished IL-36-induced IL-23 expression (Figure 2.4 B).  
Similar to the other components of the NF-B family of transcription factors, c-Rel 
complexes with proteins to facilitate downstream gene expression. Complexes of c-Rel can be 
either c-Rel/c-Rel, c-Rel/p50 or c-Rel/p65, so we sought to determine which NF-B proteins 
besides c-Rel may be involved in IL-36-induced IL-23 expression. BMDCs from WT mice that 
were stimulated with IL-36 induced robust secretion of IL-23, and this effect was significantly 
inhibited (~60%) by p50 inhibitor peptide, but not p65 inhibitor peptide (Figure 2.4 C). 
Furthermore, BMDCs generated from NF-Bp50-deficient mice (p50-/-) and stimulated with IL-
36 showed significantly lower IL-23 expression (~3 fold) compared to those from WT (p50+/+) 
mice (Figure 2.4 D). We next performed ChIP assays to assess p50 and c-Rel binding to the IL-
23p19 promoter in BMDCs treated with IL-36𝛾. As shown in Figure 2.4 E, there was a significant 
increase in c-Rel and p50 binding to the IL-23p19 promoter in response to treatment of BMDCs 
with IL-36 for 8 hours. Collectively, these results demonstrate that MyD88, c-Rel and NF-Bp50 
are part of a signaling cascade downstream of IL-36R that is involved in IL-23 expression by DCs. 
2.5.5 Systemic IL-23 administration promotes recovery from DSS-induced intestinal damage 
in IL-36R- and IL-36γ-deficient mice in association with restoring IL-22 and anti-microbial 
peptide production.  
Since IL-36-induced IL-22 production in colonic explants from DSS-treated mice was IL-
23 dependent (Figure 2.2 A), we next explored whether administration of IL-23 could rescue 
defective resolution of DSS-induced colonic damage in Il1rl2-/- mice in association with restoring 
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IL-22 and AMP expression. DSS-treated Il1rl2-/- mice received either PBS or IL-23 (0.25g) at 
days 3, 4 and 5, and DSS was discontinued at day 5 and mice were switched to regular drinking 
water to monitor recovery from DSS-induced intestinal damage. Strikingly, systemic 
administration of IL-23 to DSS-treated Il1rl2-/- mice was sufficient to promote full resolution of 
intestinal damage as DAI, colon length, and histology were similar to that observed in DSS-treated 
Il1rl2+/+mice (Figure 2.5 A-E).  
DSS induces massive damage to the intestinal epithelial barrier that allows microbes from 
the gut lumen to enter the underlying lamina propria. The physiological immune response to this 
damage is the induction of IL-22 and AMPs including S100A8, S100A9 and members of the Reg3 
family (Reg3, Reg3, Reg3) [96].  Since IL-22 and AMPs are critically important in resolution 
of DSS-induced intestinal damage, we next examined if Il1rl2-/- mice were defective in AMP 
expression following treatment with DSS and if this could be reversed by IL-23 administration. 
Following DSS-treatment for 5 days, Il1rl2+/+mice expressed high levels of IL-22 and AMPs, 
particularly, S100A8, Reg3, and Reg3. Consistent with their inability to induce IL-22 (Figure 
2.6 A), Il1rl2-/- mice were significantly impaired in S100A8, Reg3, and Reg3 mRNA expression 
in response to DSS-treatment, and this defect was nearly completely reversible to administration 
of IL-23. Indeed, delivery of IL-23 to Il1rl2-/- mice was sufficient to induce S100A8, Reg3, and 
Reg3 to normal levels detected in Il1rl2+/+mice (Figure 2.6 B-E).  
Having observed that Notch2cKO mice, like Il1rl2-/- mice, failed to recover from DSS-
induced intestinal damage and failed to express IL-23 and IL-22 in vitro, we next attempted to 
rescue these mice by injecting IL-23. The administration of IL-23 to Notch2cKO mice was able to 
significantly reduce DAI and restore colon length (Figure 2.10 A and B) while also normalizing 
tissue architecture and histology scores to levels detected in Notch2fl/fl mice (Figure 2.10 C and D). 
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IL-23 treatment of Notch2cKO mice also induced IL-22 expression to similar levels as seen in 
control Notch2fl/fl mice (Figure 2.10 E). Furthermore, delivery of IL-23 to Notch2cKO mice was 
sufficient to induce Reg3 and Reg3 (Figure 2.10 F and G).  
We next sought to determine if our observations using Il1rl2-/- mice were predominantly 
due loss of IL-36 signaling, or if other IL-36 agonist cytokines (IL-36, IL-36) could be playing 
a role. To do so, we first treated IL-36-deficient mice (Il1f9-/-) and control mice (Il1f9+/+) with 
DSS and at day 3, colonic tissues were harvested and analyzed for IL-36, IL-36 and IL-36 
expression. In the absence of DSS, IL-36 and IL-36 were not detectable in Il1f9+/+and Il1f9-/- 
mice, while DSS-treatment of Il1f9+/+mice led to the robust expression of IL-36, and only very 
low levels of IL-36 and undetectable levels of IL-36 expression. As expected, Il1f9-/- mice had 
undetectable levels of IL-36 and did not appear to induce IL-36 or IL-36 to compensate for the 
loss of IL-36 (Figure 2.11 A). Interestingly, Il1f9-/- mice appeared to phenocopy Il1rl2-/- mice in 
response to DSS treatment in that they exhibited grossly impaired IL-23 and IL-22 production in 
colonic explants when compared to control Il1f9+/+ mice, and this defect could be overcome by 
the addition of IL-36 (Figure 2.11 B and C). To extend these in vitro observations to the in vivo 
setting, Il1f9-/- mice were treated with DSS in the presence or absence of IL-23 administration as 
in Figure 2.6. Similar to effects observed in Il1rl2-/- mice, treatment of Il1f9-/- mice with IL-23 was 
able to significantly reduce DAI (Figure 2.12 A) and normalize colon length (Figure 2.12 B and 
C) and histological damage to that seen in control Il1f9+/+ mice (Figure 2.12 D and E). IL-23 
treatment of Il1f9-/- mice further restored IL-22 (Figure 2.13 A) and AMP expression, particularly 
S100A8, Reg3, and Reg3 back to levels observed in Il1f9+/+ mice (Figure 2.13 B-F). 
Collectively, these results demonstrate that delivery of IL-23 to Il1rl2-/- mice and Il1f9-/- mice is 
sufficient to restore IL-22 and AMP expression and recovery from acute intestinal damage.  
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Since intercellular tight junctions are essential for maintaining the integrity and function of 
the intestinal barrier in the steady-state and following damage [97], we next assessed whether the 
mRNA expression of the tight junction components occludin and claudin 2 were affected by the 
loss of IL-36 signaling. Following treatment with DSS for 5 days, both Il1rl2-/- and Il1f9-/- mice 
exhibited significantly reduced occludin and claudin 2 mRNA expression, when compared to wild-
type controls. Additionally, IL-23 administration was able to restore occludin and claudin 2 mRNA 
expression to wild-type levels (Figure 2.14 A-D). These data suggest that signaling via IL-36R not 
only induces IL-23-dependent mucosal protection via IL-22 and AMP expression, but also may 
help to reseal the damaged intestinal epithelial barrier via effects on tight junctions.     
Given the dynamic crosstalk between the mucosal immune system and the gut microbiota 
[98-100], combined with the established involvement of IL-23, IL-22, and AMPs in controlling 
the microbiota [101, 102], we next explored the contribution of the IL-36/IL-36R axis in regulating 
microbiota composition. In the steady state, we observed that Il1rl2-/- mice had a significant 
increase in several flagellated bacterial groups including Clostridium cluster XIVa and XI and 
Oscillibacter, and significant decreases in the non-flagellated bacterial groups Bacteroides, 
Prevotella, and Lactobacillus (Figure 2.15 A). Interestingly, most of these changes were further 
augmented upon DSS treatment (Figure 2.15 B). These observations support a potential role for 
the IL-36/IL-23/IL-22/AMP axis in control of the microbiota during health and disease and future 
studies using 16S rRNA sequencing should further clarify the full extent to which this cytokine 
axis influences the microbiota. 
2.6 Discussion 
In this study, we provide evidence demonstrating that the IL-36/IL-36R pathway acts as a 
key upstream inducer of IL-23/IL-22/AMP-dependent colonic tissue repair. While IL-36 ligands 
27 
are well-appreciated to promote chronic inflammation and contribute to pathological tissue 
damage [49, 83, 103], their role in mediating tissue protection in response to acute insult is newly 
emerging [55, 85, 92]. We and others have recently reported that IL-36R-deficient mice treated 
with DSS have reduced signs of intestinal inflammation during the damage phase of disease, yet 
are impaired in mucosal healing [43, 55, 85]. These data suggest that the pro-inflammatory 
functions of the IL-36 pathway are intimately linked with epithelial regeneration, tissue repair, and 
healing of intestinal damage and act as part of a feedback loop that then limits further production 
of pro-inflammatory factors and pathological inflammation. IL-36 cytokines may likewise 
function to promote wound repair at other barrier surfaces, such as the skin. In this regard, a recent 
report observed that IL-36 was induced in a model of skin injury and signaling via IL-36R 
promoted wound healing via the induction of Reg3 [92]. Whether or not IL-23 and/or IL-22 were 
also involved in IL-36R-mediated wound repair in this skin model remains an open question.  
The IL-36/IL-23/IL-22 inflammatory cytokine cascade in response to DSS-mediated 
intestinal injury is a highly orchestrated process that involves numerous innate immune cell 
subsets. Early following DSS-induced damage, inflammatory monocytes/macrophages are a main 
source of IL-36 in response to components of the microbiota [55], however keratinocytes [104], 
myofibroblasts [89, 90], and other cells types may also be important sources of IL-36 cytokines 
[87]. While many cell types express IL-36R, we found that IL-36R expression was dramatically 
increased early following DSS treatment at a time that coincided with accumulation of 
CD11b+CD103+ DCs. Furthermore, in Notch2cKO mice that lack CD11b+CD103+ DCs, IL-36R 
expression was not increased following DSS treatment suggesting that Notch2-dependent 
CD103+CD11b+ DCs are recruited into the inflamed colon where they express high levels of IL-
36R and produce IL-23 in response to IL-36 stimulation. These data are consistent with several 
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reports demonstrating that CD103+CD11b+ DCs are a main source of IL-23 [78, 105], and now 
directly link IL-36R signaling to IL-23 production by these cells for the first time. Following 
secretion of IL-23, numerous cell types in the colon express IL-23R [106-108] and are capable of 
producing IL-22 [68, 71, 109]. While ILC3s are the most well-documented IL-22 producers in the 
gut [70, 110, 111], activated neutrophils [55, 75, 112] and NK cells [73] can also produce IL-22 
in response to IL-23 stimulation, and the relative contribution of IL-22 from these sources during 
intestinal damage and repair remain unclear. Additionally, IL-23R signaling directly in intestinal 
epithelial cells was recently shown to induce Reg3 and CXCL1 expression, and the recruitment 
and activation of IL-22-producing neutrophils [113]. Regardless of the source, IL-22 is a potent 
inducer of epithelial proliferation, mucus production, and anti-microbial peptide expression, all of 
which support efficient intestinal tissue repair [76, 114, 115].   
Several lines of evidence are consistent with the IL-36/IL-36R axis playing a central role 
in IL-23/IL-22/AMP-dependent resolution of acute intestinal damage. First, IL-36R and IL-36-
deficient mice are grossly impaired in their ability to recover from DSS-induced intestinal damage 
and this phenotype can be rescued by treatment with IL-23 as well as an IL-22-inducing aryl-
hydrocarbon receptor agonist [55]. Second, mice deficient in IL-23 [116] and IL-22 [73] appear to 
phenocopy the defective tissue repair in response to DSS that we observed in IL-36R and IL-36-
deficient mice. Third, Notch2cKO mice, which lack CD103+CD11b+ DCs are also defective in 
colonic repair, an effect that can also be rescued by treatment with IL-23. Of note, the defective 
repair in Notch2cKO mice was not as profound as that in IL-36R and IL-36-deficient mice, 
suggesting that other cell types aside from CD103+CD11b+ DCs may also be involved in IL-36-
induced IL-23 production.  
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Both IL-36 cytokines and IL-23 are potent inflammatory cytokines that function in a 
context-dependent manner.  In models of acute barrier damage that predominantly involve innate 
immune activation, the pro-resolution functions of these cytokines likely dominate over their pro-
inflammatory effects on T cells and the net result may be beneficial to the host. Alternatively, in 
chronic conditions where T cells play a major role, pro-inflammatory effects of IL-36 cytokines 
and IL-23 may dominate over barrier protective effects and exacerbate disease pathology. This 
appears evident during skin and intestinal inflammation where CD4+ T cells are involved [54, 84, 
87, 117-119]. Importantly, monoclonal antibody-mediated blockade of the p40 subunit of IL-12 
and IL-23 is approved for the treatment of moderately to severely active Crohn’s disease, and 
specific IL-23 blockers are showing efficacy in clinical trials [120]. Thus, our data demonstrating 
that the IL-36/IL-36R axis augments IL-23 expression in the intestine may inform on potential 
therapeutic targeting of IL-36 cytokines and/or IL-36R as a novel strategy to limit pro-
inflammatory effects of IL-23 during human IBD.  
The context-dependent role of IL-36 cytokines in inducing pro-inflammatory responses 
that lead to intestinal barrier protection appears to be an emerging paradigm for members of the 
IL-1 family cytokines [81, 82, 121]. While IL-1 augments colonic inflammation, IL-1 is 
involved in restitution of the epithelial barrier and resolution of acute colonic damage [122]. 
Similarly, NLRP6, ASC, caspase-1, and IL-18 are all protective in the DSS model of colitis [123, 
124].  The alarmin IL-33 can also promotes intestinal tissue protection via the amphiregulin-EGFR 
pathway and act on ST2-expressing regulatory T cells to promote their function in suppression of 
colitis [125]. IL-37 is an atypical member of the IL-1 family in that it functions as an inhibitor of 
innate inflammation and immunity, yet still functions to protect from colitis in mice [126, 127]. 
Our data indicate that IL-36 and IL-36R are rapidly induced following acute colonic damage and 
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orchestrate a key inflammatory process involving CD103+CD11b+ DCs, IL-23, IL-22, and AMPs, 
which ultimately functions to resolve colonic damage and provide host protection (Figure 2.16). 
These findings have potential implications for the treatment of intestinal inflammatory conditions, 
including IBD, where the beneficial effects of IL-36 and/or IL-23 blockade may be limited by 
concomitant interference with tissue repair processes.  Therefore, a combined therapeutic approach 
aimed at inhibiting pro-inflammatory cytokines, while augmenting tissue repair mechanisms may 
afford optimal treatment for chronic intestinal inflammation.    
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2.7 Figures and figure legends 
Figure 2.1 IL-36R-deficiency results in impaired IL-23 and IL-22 expression in the colons of 
DSS-treated mice. 
 
(A) PCR array gene expression analyses from colon tissues of Il1rl2+/+ and Il1rl2-/- mice treated 
with DSS for 5 days. (B-C) Time course of IL-23 mRNA (B) and protein (C) expression in colons 
from Il1rl2+/+ and Il1rl2-/- mice treated with DSS. (D-E) Time course of IL-22 mRNA (D) and 
protein (E) expression in colons from Il1rl2+/+ and Il1rl2-/- mice treated with DSS. Data are 
representative of 3 independent experiments with 3-4 mice/group. All data are presented as mean 




Figure 2.2 IL-36-induced IL-22 production in colonic explants from DSS-treated mice is IL-23 
dependent. 
  
(A-B) Colonic explants from control (no DSS) or 3-day DSS-treated (3d DSS) WT mice were 
cultured for 60h in the presence or absence of IL-36𝛾. (A) Supernatants were analyzed for IL-23 
(A) and IL-22 (B) by ELISA. (C) Colonic explants from 3-day DSS-treated WT mice were 
stimulated with IL-36𝛾 and αp19 or αp40 antibodies for 60h and IL-22 expression was assessed 
by ELISA. (D) Colonic explants from 3-day DSS-treated WT (Il12b+/+) or Il12b-/- mice stimulated 
with IL-36𝛾 or IL-23 for 60h and IL-22 expression was assessed by ELISA. Data are representative 
of at 2 independent experiments with 4-5 mice/group. All data are presented as mean ± SEM; n.s.= 









































Figure 2.3 Notch2-dependent DCs are required for IL-36-induced IL-23 and IL-22 expression 
and recovery from colonic damage.  
 
(A) IL-36R (Il1rl2) mRNA expression was analyzed by qPCR in colon tissue isolated from DSS-
treated batf3+/+, batf3-/-, Notch2fl/fl and Notch2cKO mice directly ex vivo. (B-C) Colonic explants 
from DSS-treated mice were cultured for 60h in the presence or absence of IL-36𝛾 or IL-23. 
Supernatants were analyzed for IL-23 (B) and IL-22 (C) expression by ELISA. (D) DAI of batf3+/+, 
batf3-/-, Notch2fl/fl and Notch2cKO mice treated with DSS for 5 days, followed by normal water. (E) 
Image and colon length from mice treated as in (D), at day 14. (F-G) Expression of IL-23 (F) and 
IL-22 (G) in colon tissues from DSS mice at day 5.  Data are representative of 2 independent 
experiments with 3-4 mice/group. All data are presented as mean ± SEM; n.s.= not significant; *P 




Figure 2.4 IL-36 induces IL-23 via signaling through c-Rel and NF-Bp50 
(A) BMDC were generated from c-rel+/+ and c-rel-/- mice and cultured in the presence or absence 
of IL-36𝛾 for 24 hr and IL-23 was assessed by ELISA. (B-C) WT BMDC were cultured in the 
presence or absence of IL-36𝛾 for 
 24 hr and IL-23 was assessed by ELISA. (B) Some cultures were pre-treated with the c-Rel 
inhibitor (IT-603) or with vehicle control (DMSO) for 1h. (C) Some cultures were pre-treated with 
p50 or p65 inhibitor peptides or control peptides for 1h. (D) BMDC were generated from p50+/+ 
and p50-/- mice and cultured in the presence or absence of IL-36𝛾 for 24 hr and IL-23 was assessed 
by ELISA. (E) ChIP assays for p50 and c-Rel binding to the p19 promoter in BMDCs treated with 
IL-36𝛾 for 8 h. Data in (A-D) are representative of at least 2 independent experiments with n = 5. 
Data in (E) are the combined data of two independent experiments with 3 replicates per 
experiment. All data are presented as mean ± SEM; **P < 0.01, and ***P < 0.001, one-way 







Figure 2.5 Systemic IL-23 administration induces resolution of DSS-induced colonic damage in 
Il1rl2-/- mice.  
(A) DAI of Il1rl2+/+ and Il1rl2-/- mice treated with DSS for 5 days, followed by normal water for 
7d, in the presence or absence of IL-23. (B-C) Image and length of colons from mice treated as in 
(A). (D) H&E staining and (E) histology scoring of colon sections from mice treated as in (A). Data 
are representative of 3 independent experiments with 4-5 mice/group. All data are presented as 
mean ± SEM; n.s.= not significant; *P < 0.05, **P < 0.01, one-way ANOVA with Tukey’s 






Figure 2.6 Systemic IL-23 administration induces IL-22 and AMPs and rescues Il1rl2-/- mice 
from DSS-induced colonic damage.  
(A) IL-22 protein expression in colons from Il1rl2+/+ and Il1rl2-/- mice treated with DSS for 5 days 
in the presence or absence of IL-23. (B) S100A8 (C) S100A9 (D) Reg3α (E) Reg3β and (F) Reg3𝛾 
mRNA expression in colons isolated from mice as in (A). Data are representative of 2 independent 
experiments with 5-6 mice/group. All data are presented as mean ± SEM; n.s.= not significant; 




Figure 2.7 Chapter 2 S1. Expression of IL-36, IL-23, IL-22 and IL-36R during DSS treatment. 
(A) Time course analysis of IL-36g, IL-23, and IL-22 mRNA expression in colonic tissue isolated 
from WT mice during the course of DSS treatment (5 days DSS followed by 2 days of regular 
water). (B-C) Colonic explants from DSS-treated mice at day 3 DSS stimulated with IL-36 and 
IL-36 for 60h and supernatants were analyzed for IL-23. (B) and IL-22 (C) by ELISA. (D) qPCR 
analysis of Il1rl2 expression in colonic explants isolated from DSS- treated mice as in (B-C). Data 
are representative of at least 2 independent experiments with 4-5 mice/group. All data are 







Figure 2.8 Injection of anti-CSF-1R antibody does not alter IL-36γ-induced IL-23 or IL-22 
production.  
 
(A) FACS plots of total colonic lamina propria cells isolated from WT mice treated with 
neutralizing anti- CSF-1R antibody or isotype control antibody and analyzed at day 3 of DSS 
treatment. (B-C) Colonic explants from DSS-treated mice as in (A) were cultured for 60h in the 
presence or absence of IL-36! or IL-23. Supernatants were analyzed for IL-23 (B) and IL-22 (C) 
expression by ELISA. All data are presented as mean ± SEM; n.s.= not significant; one-way 







Figure 2.9 IL-36γ signaling stimulates IL-23 production in BMDCs via MyD88.  
WT (myd88+/+) or myd88-/- BMDCs were cultured for 60h in the presence or absence of IL-36γ. 
Supernatants were analyzed for IL-23   by ELISA. Data are representative of 2 independent 
experiments with 4-5 mice/group. All data are presented as mean ± SEM; ***P < 0.001, one-way 







































Figure 2.10 Systemic IL-23 administration induces the resolution of DSS-induced colonic 
damage in Notch2cKO mice.  
 
(A) DAI of Notchfl/fl and Notch2cKO mice treated with DSS for 5 days, followed by normal water 
for 7days, in the presence or absence of IL-23. (B) Image and length of colons from mice treated 
as in (A). (C) H&E staining and (D) histology scoring of colon sections from mice treated as in 
(A). (E) IL-22 protein expression in colons from Notchfl/fl and Notch2cKO mice treated with DSS for 
5 days in the presence or absence of IL-23. (F) Reg3β and (G) Reg3! mRNA expression in colons 
isolated from mice as in (A). Data are representative of 3 independent experiments with 4-5 
mice/group. All data are presented as mean ± SEM; n.s.= not significant; *P < 0.05 and ***P < 




Figure 2.11 Analysis of Il1f9-/- mice.  
(A) IL-36 ligand mRNA expression in colonic tissues from 3-day DSS- treated Il1f9+/+  and Il1f9-
/-  mice. (B) Colonic explants from control (no DSS) or 3-day DSS-treated (3d   DSS) Il1f9+/+  and 
Il1f9-/-  mice were cultured for 60h in the presence or absence of IL-36!. Supernatants   were 
analyzed for IL-23 (B) and IL-22 (C) by ELISA. n.d.= not detected. Data are representative of 2 









































Figure 2.12 Systemic IL-23 administration induces resolution of DSS-induced colonic damage in 
Il1f9-/-mice.  
 
(A) DAI of Il1f9+/+ and Il1f9-/- mice treated with DSS for 5 days, followed by normal water for 
7days, in the presence or absence of IL-23. (B-C) Image and length of colons from mice treated as 
in (A). (D) H&E staining and (E) histology scoring of colon sections from mice treated as in (A). 
Data are representative of 3 independent experiments with 4-5 mice/group. All data are presented 
as mean ± SEM; n.s.= not significant; *P < 0.05, **P < 0.01, and ***P < 0.001, one-way ANOVA 


































Figure 2.13  Systemic IL-23 administration induces IL-22 and AMPs in DSS-treated Il1f9-/- 
mice.  
 
(A) IL-22 protein expression in colons from Il1f9+/+ and Il1f9-/- mice treated with DSS for 5 days 
in the presence or absence of IL-23. (B) S100A8 (C) S100A9 (D) Reg3α (E) Reg3β and (F) Reg3! 
mRNA expression in colons isolated from mice as in (A). Data are representative of 2 independent 
experiments with 5-6 mice/group. All data are presented as mean ± SEM; n.s.= not significant; 




Figure 2.14  Systemic IL-23 administration induces expression of occludin and claudin 2 in 
DSS-treated Il1rl2-/- and Il1f9-/- mice. 
 
(A) Occludin and (B) claudin 2 mRNA expression in colons from Il1rl2+/+ and Il1rl2-/- mice treated 
with DSS for 5 days in the presence or absence of IL-23. (C) Occludin and (D) claudin 2 mRNA 
expression in colons from Il1f9+/+ and Il1f9-/- mice treated with DSS for 5 days in the presence or 
absence of IL-23. Data are combined from 2 independent experiments with 3 mice/group. All data 





Figure 2.15 Fecal microbiota composition in steady-state and DSS-treated Il1rl2-/- mice.  
Real-time PCR analysis of flagellated and non-flagellated bacterial groups in the feces of Il1rl2+/+ 
mice and Il1rl2-/- (A) before DSS treatment (no DSS) and (B) after DSS treatment. All data are 






Figure 2.16 Schematic representation of the IL-36/IL-23/IL-22/AMPs axis. 
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3 CHAPTER 3: IL-36R SIGNALING INTEGRATES INNATE AND ADAPTIVE 
IMMUNE-MEDIATED PROTECTION AGAINST ENTEROPATHOGENIC 
BACTERIA 
Vu L. Ngo, Hirohito Abo, Michal Kuczma, Edyta Szurek, Nora Moore, Oscar Medina-
Contreras, Didier Merlin, Andrew T. Gewirtz, Leszek Ignatowicz and Timothy L. Denning 
3.1 Abstract 
Infection with enteropathogenic bacteria is worldwide health problems and associated with 
a high mortality rate in developing countries. Efficient host protection against enteropathogenic 
bacterial infection is characterized by proper coordination responses between epithelial cells, 
innate, and adaptive immunity. In response to infection, the immune cells are activated to produce 
interleukin (IL)-22, which is involved in induces antimicrobial peptides to eliminate bacteria. The 
IL-36 cytokines are recently described members of IL-1 superfamily cytokines known to exert 
potent resolution of mucosal damages during acute intestinal inflammation via the induction of IL-
22 and epithelial cell proliferation. IL-36R-deficient mice have reduced IL-22 expression; thus, 
these mice are more susceptible to acute intestinal inflammation and bacterial infection. Using a 
restricted mouse pathogen, Citrobacter rodentium, as a model to study intestinal bacterial 
infection, we demonstrated IL-36 signaling is a crucial component that helped linked epithelial 
cells, innate and adaptive immunity together to ward off intestinal bacterial infection. We showed 
that Il1rl2-/- mice exhibiting decrease in AMPs, increase intestinal damage, and failed to resistance 
to bacterial colonization compared to wild-type control mice. This defective is associated with 
prominent downregulation of IL-23 and IL-6, two potent IL-22 inducers. Exogenous IL-23 
administration during the early phase of bacterial infection mediated ILC3/IL-22 protection 
in Il1rl2-/- mice. Whereas administration of IL-6 during the late phase of infection, mediated IL-
48 
22 dependent CD4+ T cells protection. We also show the intracellular signaling cascade for IL-36γ 
induces IL-6/IL-22 involves signaling through NFB-p65 subunit and the activation of aryl 
hydrocarbon receptor. Collectively, these data indicated that IL-36 signaling is providing critical 
host defense against intestinal bacterial infection.  
3.2 Introduction 
Attaching and effacing bacterial infection (A/E infection) of the gastrointestinal tract 
represents a significant cause of mortality worldwide and continues to pose a threat to global 
health. Human enteropathogenic Escherichia coli (EPEC) and enterohemorrhagic E. coli (EHEC) 
are the two common A/E bacterial infections and have been associated with a high infant mortality 
rate in developing nations. Up to date, much of our knowledge on how the host's response to A/E 
infections is derived from experimental studies with Citrobacter rodentium, a gram-negative 
mouse-restricted pathogen. C. rodentium colonizes the host's intestinal mucosal layer via the 
formation of attaching and effacing lesions that result in a breach of the intestinal epithelial barrier, 
leading to colitis via robust inflammatory responses [128-130].  
Effective host protection against A/E bacterial infection is characterized by the combined 
responses of intestinal epithelial cells, innate and adaptive arms of the immune system. The 
intestinal epithelial cells produce antimicrobial peptides to control the pathogens [131]. Studies 
of C. rodentium infection in immune-deficient mouse strains have recognized the crucial role of 
innate lymphoid cells 3 (ILC3), and CD4+ T cells are essential components of the innate and 
adaptive immunity used for containing and eliminate bacterial [132-135]. Cytokines secrets from 
immune cells, including interleukin (IL)-22, IL-23, and IL-6, have an important role in host 
defense during C. rodentium infection. IL-22 plays a vital role in control the gut flora and 
pathogenic bacterial and is secreted by a heterogeneous population of immune cells. IL-22 
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control C. rodentium infection by stimulates the secretion of antimicrobial peptides in epithelial 
cells. Consequently, mice lacking this cytokine rapidly succumb to the disease [74, 131-133, 136-
138]. 
The IL-1 family of cytokines is central to protective mucosal immunity in bacterial 
infection [139]. The IL-1 family of cytokines comprises seven agonistic cytokines and one anti-
inflammatory member. IL-36 cytokines are a member of the larger IL-1 family and include three 
agonist proteins and one antagonist. IL-36 agonists bind to IL-36R complex and trigger immune 
responses. IL-36R is widely expressed on numerous cells, including murine dendritic cells, naïve 
CD4+ T-cells, epithelial cells of tissues such as the skin, intestine, and lung. Similar to their 
receptor, IL-36 ligands are expressed by a variety of cells dependent on the tissues and disease 
condition. In the murine model of acute intestine inflammation, IL-36 expressed by inflammatory 
monocytes and epithelial cells. IL-36 agonist mediates broad proinflammatory effects, including 
cytokines/chemokines production, DC maturation, and T-cell differentiation [34, 35, 66, 67]. IL-
36 research has mainly focused on skin diseases; however, in the last decade, the role of IL-36 
cytokines in intestine biology has emerged. Our group and others previously demonstrated that IL-
36 cytokines undertake a central role in mediates the resolution of the intestinal mucosal damages 
in acute intestinal inflammation by facilitates epithelial cell proliferation and the production of IL-
22, and antimicrobial peptides. IL-36R-deficient mice are more prone to DSS-induced acute 
intestinal inflammation and intestinal/lung bacterial infection [45, 47, 55, 56]. 
In this study, we tested the hypothesis that an IL-36R agonist, IL-36γ, shape the host 
immunity in the murine intestines caused by C. rodentium infection. We found that IL-36α and 
IL-36γ are expressed in the large intestine during C. rodentium infection and that it mediates 
bacterial clearance in the intestines, innate inflammatory cells trafficking, cytokines/chemokines 
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expression. Moreover, we identify a critical role of IL-36 as a central component of innate and 
adaptive immune responses during C. rodentium infection. Specifically, our finding indicates in 
the early phase of infection, IL-36R signaling in promoting IL-23 release, which subsequently 
regulates the protective function of ILC3. During the late phase of infection, IL-36R signaling 
contributes to host defense by induces the expression of IL-6 and consequently directed the 
differentiation of naïve CD4+ T cells into IL-22 producing CD4+ T cell. Unlike IL-36R-sufficient 
mice, Il1rl2-/- succumbed to C. rodentium infection due to the profound downregulation of IL-22 
as compared to control mice. Administration of exogenous IL-23 in the early phase, or IL-6 in the 
late phase, protected Il1rl2-/- mice from C. rodentium induced intestinal inflammation. 
Mechanistic experiments revealed that upon infected with C. rodentium, inflammatory secreted 
IL-36γ and led to the activation of NFB in dendritic cells and subsequent induction of IL-23 and 
IL-6, which in turn promoted a protection of ILC-3 and CD4+ T cells mediated IL-22 response. 
3.3 Materials and Methods 
3.3.1 Mice 
The following mice were purchased from The Jackson Laboratory: WT C57BL/6 (B6 WT), 
B6.129P-Nfkb1tm1Bal/J (p50-/-), B6.129P2(SJL)-Myd88tm1.1Defr/J (myd88-/-), B6.SJL-Ptprca 
Pepcb/BoyJ (CD45.1), B6.129S6-Tbx21tm1Glm/J (tbx21-/-). Il1rl2-/- (IL-36R-/-) mice on the C57BL/6 
background (backcrossed more than nine generations) were originally provided by Amgen. To 
generate Il1f9-/- (IL-36γ-/-mice, sperm from IL-36γ-/- mice was obtained from Knockout Mouse 
Project repository (University of California, Davis), and heterozygous Il1f9+/- founder mice were 
generated by Mouse Transgenic and Gene Target Core facility at Emory University. Il1f9+/- mice 
were then bred to generate Il1f9-/- mice on the C56BL/6 background (backcrossed more than nine 
generation). Ahr-/- mice kindly provided by Dr. Andrew Gewirtz (Georgia State University). 
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Unless otherwise stated mice were used at 4-6 weeks of age and were carried out using age and 
gender matched groups. Animal studies were approved by the Institutional Animal Care and Use 
Committee of Georgia State University.  
3.3.2 Citrobacter rodentium strain and infection 
C. rodentium strain ICC180 (derived from DBS100) was originally generated by Dr. Gad 
Frankel and Dr. Fiouxsie Wiles (Imperial College London) and was generously gifted by Dr. Casey 
Weaver (The University of Alabama, Birmingham). Mice were inoculated with 5-6 x109 colony 
forming per unit (CFU) in a volume of 200µl PBS via gastric gavage and monitored for survival 
rate, body weight changes and bacterial colonization for clinical signs of disease.  
3.3.3 Bioluminescence Imaging 
Mice were anesthetized with isoflurane and imaging with an IVIS-100 system and Living 
Image Software (Xenogen, Inc.). Baseline images were collected prior bacterial inoculation and 
whole images were taken at binning of 4 over 3-10 mins at the indicates times during infection.  
3.3.4 Gene expression analysis of RT2 profiler PCR array 
Gene expression analysis of whole colonic tissues infected with C. rodentium at day 4 and 
8 were assess using RT2 profiler PCR array (Qiagen) as previously described. Briefly, at indicated 
time point, mice infected with C. rodentium were euthanized and whole colonic tissues were 
homogenized and isolated RNA by using RNeasy mini kit (Qiagen) and the cDNA was generated 
using RT2 First Strand Kit (Qiagen) followed by genomic isolation. Profile of genes expression 
from generated cDNA were construct according to manufactured protocol.  
3.3.5 CD4+ T cell differentiation 
FACs-sorted CD4+CD25- T cells were co-culture in the presence of FACs-sorted 
CD45+MHCII+CD11c+ dendritic cells (DCs) for 72-80 hours in the presence or absence of 
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100ng/mL IL-36γ. In some experiments, monoclonal antibodies and/or pharmaceutical inhibitors 
were added in the culture as indicated per experiments. Unless otherwise stated, monoclonal 
antibodies were purchased from R&D and inhibitors were purchased from Cayman chemicals. 
3.3.6 ELISA 
IL-22 and IL-6 secretion was measured in cell-free culture supernatant using IL-22 ELISA 
kit (R&D system) and IL-6 ELISA kit (eBiosciences) according to the manufacturer’s protocol. 
3.3.7 In Vivo Administration of IL-23 and IL-6 
Recombinant mouse IL-23 and IL-6 was purchased from R&D system. All administration 
of recombinant cytokines was performed via intraperitoneal injection. For IL-23 administration, 
Il1rl2-/- mice received either PBS or 0.5µg of IL-23 at day 0 and 2 post infection. For IL-6 
administration, Il1rl2-/- mice received either PBS or 1µg of IL-6 at day 4, 6 and 8 post infection. 
3.3.8 Bone marrow-derived dendritic cells (BMDCs) and bone marrow-derived macrophages 
(BMDMs) 
BMDCs and BMDMs were generated from 6 to 15-week-old WT, crel-/-, p50-/-, myd88-/- 
mice. Bone marrow cells were harvest from femurs of mice and cultured in RPMI-1640 
supplemented with fetal bovine serum, 50µ -mercaptoethanol, and penicillin/streptomycin. 
Depend of BMDCs and BMDMs, 20ng/mL of recombinant murine granulocyte macrophage 
colony-stimulating factor (GM-CSF), or 20ng/mL of macrophage colony-stimulating factor (M-
CSF) (Peprotech, NJ) were added to cells. The generated BMDCs and BMDMs were harvested 
and 2x105 cell/well were seeded to the 96 well plates for further studies. For in vivo study of the 
induction of IL-36γ, BMDMs were stimulated with head-killed C. rodentium for 24 hours. For the 
in vivo study of how IL-36γ induces IL-6, WT BMDCs were stimulated ± IL-36γ (100ng/mL) and 
53 
± NF-B inhibitors: c-Rel inhibitor IT-603 (Calibiochem, CA), p50/or p65 inhibitor peptide 
(Novus biological, CO). 
3.3.9 Quantitative real-time PCR 
Total RNA was isolated from mice colonic tissues using the Qiagen RNeasy Mini Kit 
according to manufacturer’s protocol. cDNA was generated with Superscript First Strand 
Synthesis kit according to manufacturer’s protocol. Q-PCR was performed with SYBR green 
(BioRad, CA) using a StepOnePlus PCR system (Applied Biosystem, CA) and gapdh were used 









































Fwd 5'- GCT GGA AGT AGA TGA GTG TGC TC -3' 
Rev 5'- CAC AGA CCT TGC CAT AGA AGC C -3' 
Dll2  
Fwd 5'- CCA GCA CTG GAT GCC TTT TAC C -3' 
Rev 5'- ACC TCA CAT CGA AGC CCG TAG A -3' 
Dll4  
Fwd 5'- GGG TCC AGT TAT GCC TGC GAA T -3' 
Rev 5'- TTC GGC TTG GAC CTC TGT TCA G -3' 
Jagged1  
Fwd 5'- GAG ATA TAC CGC ACC CCT TCA G -3' 
Rev 5'- ACC ACC TGC GAA GTG ATT GAC -3' 
Jagged2  
Fwd 5'- TCC TCA TCT GGA GTG GTG TCA T -3' 
Rev 5'- CGT CGT CAT TCC CTT TCA GTT C -3' 
3.3.10 Chromatin Immunoprecipitation assay (ChiP) 
BMDC were cultured with ± IL-36γ (100ng/mL) for 6 hours. ChiP assay were performed 
with EZ-ChiP kit (EMD Millipore 17371) as previous described (PNAS paper). Briefly, chromatin 
was obtained from BMDCs after fixation with formaldehyde and fragmented by sonication. One 
tenth of each fragmented sample were saved prior to immunoprecipitation for input control. The 
fragmented sample was immunoprecipitated with control antibody or anti p50 (clone SC-8418), 
anti c-rel (clone sc-6955) (Santa Cruz Biotechnology, CA), or anti p65 (clone K310) (Abcam, 
MA). Input sample and DNA recovered from the immunoprecipitation were analyzed by qPCR. 
56 
3.3.11 Histology 
Colon tissues were fixed in 10% neutral formalin buffer. Paraffin embedding, sectioning 
and hematoxylin/eosin staining, and slide scanning were performed at Histowiz, Inc. (New York). 
3.3.12 Statistical analysis 
All statistical analyses were done with GraphPad Prism software, version 8.0. One-way 
ANOVA and Tukey’s multiple comparison or Student’s t test were used to determine significance 
(*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, ns not significance). 
3.4 Results 
3.4.1 IL-36γ and IL-36α are induced in the large intestine during C. rodentium infection.  
In order to establish the role of IL-36 in response to intestinal bacterial infection, we assessed 
whether IL-36 agonist ligands are expressed in C. rodentium infection. Wild-type mice were 
inoculating with 5-6x109 CFU of C. rodentium and the kinetic expression of Il1f6 (IL-36α), Il1f8 
(IL-36β), and Il1f9 (IL-36γ) were measured in the large intestine of infected mice over twelve 
days. Between the three agonists, the IL-36γ transcript was express at the earliest, beginning at 
day one, and peaking at day six then steadily declining after eight-day post-infection (Figure 3.7 
A). IL-36α were transcribed on day two with the level of expression steadily increasing over a 
twelve days period post-infection (Figure 3.7 B). In contrast to IL-36α and IL-36γ, no IL-36β was 
not detected in the C. rodentium infected large intestine (Figure 3.7 C). In this study, we have 
opted to focus on IL-36γ as it is the preferred IL-36 ligand expressed during experimental intestinal 
inflammation in mice, and all the IL-36 agonists had been shown to have similar functions. 
 IL-36γ expression has been observed in several cell types ranging from the hematopoietic 
to the non-hematopoietic compartment in different murine models of inflammation, because of 
this, we analyzed several immune cells population for IL-36γ RNA at day six post-infection. 
57 
Among immune cell populations, CD11b+Ly6C+ inflammatory monocytes were the most 
significant producer of IL-36γ (Figure 3.7 D). Moreover, in vivo stimulating bone-marrow derived 
macrophages (BMDMs) with heat-killed C. rodentium resulted in robust induction of IL-36γ 
(Figure 3.7 E). Collectively, these results suggested the contribution of IL-36 signaling in 
promoting intestinal immunity to C. rodentium. 
3.4.2 IL-36 signaling promotes pathogen clearance and colonization resistance against C. 
rodentium infection.  
Recently, IL-36R signaling has been shown to have prominent roles in host protection 
against oral fungal and lung bacterial infection [140-142]. To examine the significance of IL-36R 
signaling caused by enteropathogenic intestinal bacterial infection, we infected Il1rl2+/+ and Il1rl2-
/- mice with 5x109 – 6x109 colony-forming unit (CFU) of a bioluminescence C. rodentium and 
monitored weight loss, bacterial colonization, and survival rate of mice. Consistent with previous 
study [43], bioluminescence imaging of the mice’s bodies revealed that Il1rl2+/+ mice were able 
to survive the infection by completely clearing out the bacteria by eighteen days post-infection. In 
stark contrast, Il1rl2-/- mice failed to control bacterial colonization, experienced a slow bacterial 
clearance rate (Figure 3.1 A and Figure 3.8 A), and succumbed to infection starting at day ten and 
leading to a 40% mortality by day eighteen post-infection (Figure 3.1 B). Il1r2-/- mice also 
experienced a substantial drop in bodyweight (Figure 3.1 C) and had significantly higher bacterial 
shedding in feces (Figure 3.1 D). Bioluminescence imaging the mice’s organs ten days post-
infection revealed that while the bacterial load was higher in the large intestine and the caecum of 
the Il1rl2-/- mice, the C. rodentium did not spread to spleen, liver and mesenteric lymph nodes 
(Figure 3.8B). Furthermore, while IL-36R-deficient mice shown to have higher bacterial counts in 
large intestine and caecum, their peripheral organs have the similar number of bacteria compared 
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to the control mice (Figure 3.8, C to F). These data are suggested that while IL-36 signaling is 
crucial to control bacterial colonization and accelerate bacterial clearance, this pathway is 
dispensable for control the dissemination of bacteria. 
3.4.3 IL-36R-deficiency results in diminished IL-22, IL-23, and IL-6 expression in the large 
intestine during C. rodentium infection.  
We and other groups had demonstrated that mice with altered in IL-36 signaling 
experienced compromised mucosal healing and were increasingly susceptible to bacterial 
infection. For the potential mechanisms of IL-36R signaling conferred protection to host against 
intestinal bacterial infection, our search began with a PCR array on the total colonic tissues isolated 
from Il1rl2+/+ and Il1rl2-/- mice at early and late phase of infection, day 4 and 8, respectively 
(Figure 3.2 A). PCR array analysis revealed that in the early phase of infection IL-22 and IL-23 
expression was eighteenfold and ten-fold, respectively, higher in Il1rl2+/+ mice compared to Il1rl2-
/- mice (Fig. 3.2, B and D). This indicates that similar to DSS induced acute intestinal inflammation, 
during the early phase of bacterial infection, the impaired of IL-22 expression in Il1rl2-/- mice is 
correlated with the deficiency of IL-23. During the late phase of infection, the analysis showed 
that the both IL-22 and IL-6 expression was tenfold higher in Il1rl2+/+ mice compared to Il1rl2-/- 
mice (Figure 3.2, C and E). ELISA analysis of colonic tissues for IL-22, IL-23 and IL-6 protein 
expression during twelve days post-infection revealed that IL-23, IL-6 and IL-22 was significantly 
higher in colonic tissue isolated from Il1rl2+/+ mice compared to Il1rl2-/- mice (Figure 3.2, F to H). 
Previous studies indicated that IL-22 is the crucial component in host protection again intestinal 
enteric bacteria, and that, while the early wave of IL-22 production is dependent on IL-23, the 
second wave of IL-22 is dependent on IL-6. These previous findings, in conjunction with our data, 
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implies that IL-36 signaling potentially participates in both the innate and adaptive arms of the 
immune systems in response to intestinal bacterial infection.  
Of note, IL-36 signaling also implicating in control the recruitment of inflammatory innate 
immune cells during bacterial infection. Thus, we questioned whether abnormalities in the IL-36 
pathway could affect the recruitment of immune cells to the large intestine during bacterial 
infection. Analysis of the innate immune subset at the early phase (day 4) and the late phase (day 
8) of infection revealed no difference in the percentage of inflammatory monocytes (CD11b+LyC+) 
and neutrophils (CD11b+Ly6G+) during the early phase of infection, however, these two subsets 
are significantly elevated during the late phase (Figure 3.9, A to C). The elevation of both 
inflammatory monocytes and neutrophils in Il1rl2+/+ mice corresponds to the increased gene 
expression of neutrophil chemoattractant cxcl1 and cxcl2 (Figure 3.9, D and E), as well as 
monocyte chemoattractant, cxcl3 and cxcl5 (Figure 3.9, F and G). 
3.4.4 Early administration of IL-23 rescues Il1rl2-/- mice from C. rodentium infection.  
Our group demonstrated that IL-36 cytokines induce IL-22 is IL-23-dependent and the 
administration of IL-23 can rescue Il1rl2-/- mice from DSS-induced acute colonic damage. As IL-
23 is essential for host protection in the early phase of bacterial infection, we postulated that the 
injection of IL-23 could confer protection to Il1rl2-/- mice against C. rodentium infection. C. 
rodentium infected Il1rl2-/- mice received either PBS or rIL-23 (0.5ug) at day 0 and 2 post-
infection, and mice were monitored for bacterial clearance, change in body weight, and survival 
(Figure 3.3 A). Systemic administration of IL-23 to C. rodentium infected Il1rl2-/- mice was able 
to accelerate bacterial clearance, improved survival rate, and body weight (Figure 3.3, B to E). 
Furthermore, the histology of infected Il1rl2-/- mice was similar to those observed in Il1rl2+/+ mice 
(Figure 3.3 F and G). Antimicrobial peptides (AMPs) induced by IL-22, including S100A8, 
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S100A9 and RegIII family, are crucial for the host’s defense again bacterial infection. Thus, we 
investigated whether Il1r2-/- mice exhibit decreased AMP expression during C. rodentium 
infection. Due to their inability to induce IL-22, consequently Il1rl2-/- mice experienced a 
significantly diminished expression of AMPs compared to that of wild-type mice at four days post-
infection. This defect appeared to be nearly reversible by delivering exogenous IL-23 (Figure 3.3, 
H to K). 
We next determined which immune cell populations in the IL-36 pathway produced IL-22 
in response to exogenous IL-23. Il1rl2-/- mice infected with C. rodentium were treated with rIL-23 
at days 0 and 2 post-infection. They then received either CD90 antibody to deplete T-cell and 
ILC3 populations or αCD4 to deplete CD4+T-cells. As expected, the Il1rl2-/- mice treated with IL-
23 eliminated the bacteria and recovered while the mice treated with αCD90 failed to control 
bacterial colonization. At day 20, 60% of the mice treated with αCD90 succumbed to the disease. 
We noticed that, remarkably, the mice which had received αCD4 could only control bacterial 
colonization the first eight-day post-infection; as a result, these mice experienced a rapid decrease 
in body weight and an increase in bacterial presence (Figure 3.3, L to O). In addition, FACs data 
showed that exogenous rIL-23 failed to induce CD4+ T cells to produce IL-22 at four days post 
infection (Figure 3.10, A and B). These data indicated that while IL-36 acts on ILC3 during the 
early phase of infection; in the late phase of infection, IL-36 exerts its influences on CD4+ T cells 
to confer host protection. 
3.4.5 Administration of IL-6 during late phase of C. rodentium infection is associated with 
accelerated bacterial clearance and restoration of IL-22 production.  
We have shown that, during early bacterial infection, administration of exogenous IL-23 
can rescue host; however, this effect is interrupted in the absence of CD4+ T-cells. We also 
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observed that in the late phase of infection, Il1rl2-/- mice is experienced reduced expression of IL-
6 and IL-22. Since IL-6 is a well-known potent inducer for CD4+ T cell to produce IL-22. 
Therefore, we hypothesized that we could rescue Il1rl2-deficienct mice during the late phase of 
bacterial infection by administration of exogenous IL-6. C. rodentium infected Il1rl2-/- mice 
received either PBS or IL-6 (1ug) at days 4, 6, and, 8 and mice were monitor for 20 days (Figure 
3.4 A). Interestingly, while C. rodentium infected Il1rl2-/- mice failed to control the bacterial 
colonization in the first few days; these mice were able to accelerate bacterial clearance quickly 
upon received exogenous IL-6 (Figure 3.4 B). By day 20 post-infection, bacterial shedding in feces 
of Il1rl2-/- infected mice treated with IL-6 were comparable to that of Il1rl2+/+ infected mice 
(Figure 3.4 C). In addition, while 20% of Il1rl2-/- mice perished after 20-day post infection, 
administrated of IL-6 to Il1rl2-/- mice increased their survival rate to 100% (Figure 3.4 D), and 
these mice also lose less body weight (Figure 3.4 E) and have histology scores identical to that of 
wild-type mice (Figure 3.4, F and G).  
IL-22 and IL-6 are both critical for host protection against bacterial infection due to their 
ability to stimulate the production of appropriate antimicrobial peptides [74, 131, 137]. We next 
examined if Il1rl2-/-mice were defective of IL-22 and AMPs expression following bacterial 
infection and if this could be reserved by IL-6 administration. Following 10-day post-infection, 
Il1rl2+/+ mice expressed a high level of IL-22 and antimicrobial peptides including, RegIIIβ, 
RegIIIγ, S100A9. Consistent with their inability to produce IL-22 and IL-6, Il1rl2-/- mice were 
expressed lower levels of AMPs in response to bacterial infection. This effect could be overturned 
with IL-6 administration (Figure 3.4, H to K). However, the protective effect of IL36R/IL-6/IL-22 
signaling pathway was rendered completely ineffective when using antibody-mediated depletion 
of CD4+ T-cell in Il1rl2-/- mice (Figure 3.4, B to K). Collectively, these results demonstrate that 
62 
delivery of IL-6 to Il1rl2-/- mice is sufficient to restore IL-22 and AMPs expression, and rescues 
mice from intestinal bacterial infection.  
3.4.6 IL-36 signaling through AhR induces IL-22 from CD4+ T cells in IL-6-dependent 
manner.  
We established that IL-36 signaling affects both the innate and adaptive cells of the 
immune system to provide host protection against bacterial infections. In addition, we 
demonstrated that depletion of CD4+ T cells abrogates protection in the late phase of the disease. 
Next, we sought to explore the contribution of the IL-36 signaling axis on naïve CD4+ T-cell 
differentiation. We first investigated whether IL-36γ could regulate IL-22 secretion in vitro. Sorted 
naïve CD4+CD25- T cells and CD11c+ dendritic cells from spleens of wild-type mice were either 
cultured alone or co-cultured and stimulated with IL-36γ in the presence of CD3. In the presence 
of IL-36γ, T cells and lone-cultured DCs failed to induce IL-22; however, co-cultured T/DC cells 
produced a robust expression of IL-22 (Figure 3.5 A). Because both naïve CD4+ T cells and DCs 
had been showed to express IL-36R, we questioned whether IL-36γ was using CD4+ T cells or 
DCs to stimulate the induction of IL-22. We employed a co-culture system whereby DCs and naïve 
CD4+ T cells were isolated from Il1rl2+/+ and Il1rl2-/- mice. Interestingly, the expression of IL-
36R by DCs was found to be indispensable for the induction of IL-22 in the T/DC co-culture 
(Figure 3.5 B and Figure 3.11, A and B).  AhR and T-box transcription factor (T-bet) have been 
implicated as transcription factors for IL-22-producing CD4+ T cells. Therefore, we next examined 
whether IL-36γ signals through AHR and T-bet to differentiate naïve CD4+ T cells into IL-22-
producing CD4+ T cells. We performed T/DC co-cultures where the cells were isolated from either 
ahr+/+ or ahr-/- mice. In the presence of IL-36γ, T/DC from ahr+/+ mice have a robust induction of 
IL-22 and this effect is completely abolished when using T/DC from ahr-/- mice (Figure 3.5 C). 
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Furthermore, using a well-known pharmaceutical inhibitor CH-223191, to block AHR activation 
in T/DC co-culture sorted from ahr+/+ mice and stimulated with IL-36γ also nullified the ability of 
IL-36 to induce IL-22 expression from T cells (Figure 3.11 C). Of note, CH-223191 did not 
interfered with cells proliferation in the culture as the level IL-2 expression of CH223191-treated 
cells are comparable with the untreated cells (Fig. 3.11 D). We next explored whether the absence 
of T-box transcription factor can impact the ability of IL-36γ to induce IL-22 from T cells. Co-
cultured T/DCs isolated from t-bet-deficient mice that had been stimulated with IL-36γ resulted in 
a modest decrease in IL-22; however, this induction of IL-22 was entirely annulled in the presence 
of AhR pharmaceutical inhibitors (Figure 3.11 E). These data demonstrated that AHR is a crucial 
component in the IL-36/CD4+/IL-22 pathway. 
Gene expression analysis of colonic tissue from Il1rl2+/+ and Il1rl2-/- mice during the late 
phase of C. rodentium infection revealed that Il1rl2+/+ mice expressed a much higher amount of 
IL-6 and IL-22. In addition, in vivo administration of exogenous IL-6 can restored IL-22 secretion 
in Il1rl2-/- mice (Figure 3.4, H to J). Thus, we investigated whether IL-36γ was acting to promote 
the expression of IL-22 from CD4+ T cells via the induction of autocrine/paracrine signaling, 
including IL-6, which is a known factor for Th17/Th22 differentiation. We observed that T cell 
and DCs isolated from the spleen of wild-type mice were co-cultured and stimulated with IL-36γ 
was able to prompts a strong IL-22 expression (approximately fourfold) higher compared with 
unstimulated control. We next tested whether the blockade of IL-6 can have an impact on IL-22 
expression. Antibody-mediated neutralization of IL-6 was substantially decreased (approximately 
60%) the effect of IL-36γ on T/DC cells to induce IL-22 (Figure 3.5 E and Figure 3.12 A). Of note, 
using IL-23p19 and IL-23p40 antibodies mediated-blockade of IL-23 or T/DCs isolated from 
Il12b-/- mice, only had a modest effect in IL-22 expression when stimulated cells with IL-36γ 
64 
(Figure 3.12 A and B). Also, neutralization of IL-1β, IL-4, TGF-, IFN- and TNF- did 
not affect IL-36γ mediated IL-22 expression (Figure 3.12 A). 
3.4.7 IL-36γ induces IL-6 expression in DCs via MyD88 and NFB-p65 signaling. 
It is well-known that IL-6 is produced by antigen-presenting cells [143, 144]. Indeed, bone 
marrow-derived dendric (BMDCs) responded to recombinant IL-36γ to producing IL-6 secretion 
(Figure 3.5 F). Giving that IL-6 is an essential factor for IL-36γ to differentiate naïve CD4+ T-cell 
into IL-22-CD4+ producing T-cells, we sought to understand the signaling cascade involved in IL-
6/IL-22 induction in response to IL-36γ. We begin our investigation with MyD88 adaptor protein 
because this protein is a crucial adaptor for signaling pathways downstream of IL-1 family 
members [145]. We generated BMDCs from my88+/+ and myd88-/- mice and cultured them with 
IL-36γ. In the presence of IL-36γ, my88+/+ BMDCs induced a more robust expression of IL-6 
(approximately six-fold) compared to my88-/- BMDCs (Figure 3.13 A). Previous studies showed 
that upon interacting with its receptor, IL-36 ligands trigger an intracellular cascade leading to the 
activation of nuclear factor kappa B (NF-B) to stimulate immune responses [34, 48, 49, 56]. We 
then probed the role of NF-B in IL-36γ-induced IL-6 in dendritic cells by using a  small molecules 
inhibitor of NF-B. BMDCs generated from wild-type mice treated with the NF-B inhibitor, 
BAY 11-7082, virtually obliterated IL-36γ mediated IL-6 expression. We next investigated which 
subunits of the NF-B were involved in IL-36γ induced IL-6 expression. BMDCs from WT mice 
responded to IL-36γ stimulation and induced a robust secretion of IL-6. This effect was diminished 
approximately 70% in the presence of the p65 inhibitor peptide, but not in the presence of p50 or 
c-rel inhibitors (Figure 3.5 G). Likewise, following stimulation with IL-36γ, we observed no 
reduction of IL-6 from BMDCs generated from p50-/- and crel-/- mice (Figure 3.13 B and C). ChiP 
assay was performed to determined p50, c-rel and p65 binding to IL-6 promoter in BMDCs treated 
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with IL-36γ. As shown in Figure 3.5 H, there was a significant increase in p65 binding to IL-6 
promoter in response to treatment of BMDCs with IL-36γ for 6 hours. Together, these findings 
demonstrate that MyD88 and subunit NF-B are part of a signaling cascade downstream of IL-
36R that is involved in IL-6 expression in DCs. 
3.4.8 IL-36 signaling induces IL-22 production in CD4+ T cells is partially dependent on 
Notch ligands. 
Since in vitro neutralization of IL-6 did not completely inhibit the ability of IL-36γ to 
induce IL-22 in the T/DCs co-culture, we hypothesized that IL-36γ could potentially signal 
through other pathways to promote CD4+ T-cell production of IL-22. Recent studies have reported 
that either (1) signaling through the Notch pathway or (2) the degradation of tryptophan by the 
enzyme indoleamine 2,3 dioxygenase-1 (IDO1) to kynurenine could promotes CD4+ T cells to 
express IL-22 [4, 5]. Hence, we examined whether these two pathways could be involved in IL-
36γ’s ability to differentiate naïve CD4+ T-cell into IL-22-producing CD4+T cells. To investigate 
the role of the kynurenine pathway, we treated T/DC cells with 1-methyltryptophan (1-MT), a 
pharmaceutical compound, that block IDO1 from degrade tryptophan to kynurenines. We observed 
that in the presence of IL-36γ, 1-MT treated cells shown no detectable decrease in IL-22 from 
T/DC co-cultures (Figure 3.14 A). In addition, treated cell with 1-MT do not affect cell 
proliferation or cell’s ability to induce cytokines as IL-2, IFN-g, and IL-17A secretion level from 
1-MT treated cells are comparable with nontreated cells (Figure 3.14 B to D). Next, we sought to 
define the role of Notch signaling in the IL-36R/IL-22 pathway. Cells were treated with GSI, a 
pan-Notch inhibitor. The secretion of IL-22 in T/DC was reduced by approximately 40% in the 
presence of GSI and IL-36γ (Figure 3.6 A). 
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Having found that IL-36γ can use the Notch pathway to induce IL-22 from CD4+ T cells, 
we next sought to determine which notch ligands were involved in the IL36γ/Notch/IL-22 cascade. 
The canonical notch signaling pathway has five ligands: delta-like protein 1 (dll1), delta-like 
protein 3 (dll3), delta-like protein 4 (dll4), jagged 1 (jag1) and jagged 2 (jag2); these ligands are 
responsible for the majority of the Notch signaling effect. BMDCs were generated from wild type 
mice and stimulated with IL-36γ. FACs analysis and qPCR analysis revealed that IL-36γ mediated 
the upregulation of dll1 and dll4 among the five Notch ligands (Figure 3.6 B and C and Figure 3.6 
G to I) and found no detectable changes for dll3, jag1, and jag2 (Figure 3.6 D to F). We then 
assessed whether a DLL1 and DLL4 blockade could have an impact on IL-36γ induced IL-22 
expression in co-cultured T/DCs.  While antibody-mediated neutralization of DLL1 showed a 
minimal effect on IL-22, blockade of DLL4 drastically diminished IL-22 (approximately 30%). 
Consistently, neutralization of both IL-6 and DLL-1/4 completely terminated the effect of IL-36γ 
induces IL-22 in T/DC co-culture (Figure 3. 6 J).  
Base on the data presented on this report, we proposed a following model for the role of 
IL-36 signaling in host protection against intestinal inflammation: upon C. rodentium infection, 
inflammatory monocytes release IL-36 agonists and the IL-36 bind its cognate receptor complex 
on dendritic cells and triggers a signaling cascade mediating the secretion of IL-23, IL-6 and notch 
ligands (DLL1/4). While IL-23 binds its receptor on ILC3 to propagate the production of IL-22 
and subsequently AMPs to promote protection during early phase of infection; IL-6 and notch 
ligands bind to their respective receptors on CD4+ T cells to activate AHR and ultimately 
differentiate naïve CD4+ T cells into IL-22-producing CD4+ T cells to promote protection for host 
during late phase of infection (Figure 3.15). 
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3.5 Discussion 
In this study we provide evidence demonstrating that signaling via IL-36R critical for control 
of a model enteric bacterial pathogen – Citrobacter rodentium. Mice deficient in IL-36R exhibited 
decreases in AMPs, increase intestinal damage, and impaired resistance to bacterial colonization. 
These defects were associated with diminished IL-23 and IL-6 – the respective early and late 
inducers IL-22. Consistent with these data, exogenous IL-23 administration during the early phase 
of bacterial infection mediated ILC3/IL-22 protection in Il1rl2-/- mice, whereas administration of 
IL-6 during the late phase of infection, mediated IL-22-dependent CD4+ T cell protection. Our 
data also demonstrate that IL-36γ induces IL-6/IL-22 via NFB-p65 and aryl hydrocarbon 
receptor-dependent mechanisms. Overall, these data highlight a fundamental contribution of 
signaling via the IL-36/IL-36R axis to the early (innate) and late (adaptive) control of enteric 
bacterial infection and colitis. 
Previous data have established that type 3 innate lymphoid cell (ILC3) production of IL-
22 is instrumental in driving early host protection against Citrobacter rodentium [74]. Mice 
deficient in IL-22, cannot control Citrobacter rodentium expansion and rapidly succumb to 
infection. In addition to early IL-22 production by ILC3, late expression of IL-22 by CD4+ T cells 
is also critical for protection against Citrobacter rodentium. Interestingly, while early IL-22 
production by ILC3s is IL-23 dependent, late IL-22 production by CD4+ T cells was shown to be 
IL-6 dependent and IL-23 independent [131, 146]. Therefore, unique cytokines induce IL-22 
during distinct windows of enteric bacterial infection. Our data presented here demonstrate that 
signaling via IL-36R is an important upstream inducer of both early IL-22 production by ILC3s as 
well as late IL-22 production by CD4+ T cells. 
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We have previously reported that IL-36 ligands – particularly IL-36γ, were induced in the 
DSS model of colitis and IL-36 γ was similarly induced in the intestine following Citrobacter 
rodentium infection. In the absence of signaling via IL-36R, the induction of IL-23 and IL-6 were 
both dramatically reduced, as was early and late IL-22 expression. Importantly, IL-36R-deficient 
mice could be rescued from uncontrolled Citrobacter rodentium infection by exogenous 
supplementation of IL-23 early or IL-6 late. Consistent with the DSS model of colitis, signaling 
via IL-36R affords critical host protective effects through the induction of IL-22 and AMPs. Thus, 
the inflammatory role of IL-36 is instrumental to barrier protection from acute damage as well as 
transient bacterial infection. This contrasts with the pathogenic role of IL-36R signaling during 
chronic intestinal inflammation [46], such as observed in the oxazolone model of colitis where IL-
36 induces potent TH9 expansion and Treg inhibition to enhance disease [54].  
Our study indicates that therapeutic targeting of IL-36R in inflammatory processes, such 
as inflammatory bowel disease (IBD), may be optimized by a clear understanding of the dual roles 
this pathway plays in acute and chronic conditions. It is attractive to envisage blockage of IL-36R 
while concomitantly delivering IL-22 and/or AMPs in order to ameliorate pathogenic 
inflammation while promoting barrier recovery. This concept may not only apply to the IL-36 
pathway, but also other IL-1 family members, and even other inflammatory cytokines such as IL-
17A that have both inflammatory and barrier protective functions. Additionally, our data may 
provide insight into reasons for the lack of long-lasting beneficial effects of some biological 
therapies used to treat ulcerative colitis and Crohn’s disease.   
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3.6 Figures and Figures Legends 
 
Figure 3.1 IL-36 signaling promotes pathogen clearance and colonization resistance against C. 
rodentium infection.  
 
Four to six-week-old Il1rl2+/+ and Il1rl2-/- mice infected with bioluminescence C. rodentium (5-
6x109 CFU) by gastric gavage. (A) Serial whole-body imaging of Il1rl2+/+ and Il1rl2-/- mice at 
indicated time points. Images are representative of 2 independent experiments. (B to D) (B) 
Survival rate; (C) Average body weight changes; (D) Bacterial shedding in feces of infected 
Il1rl2+/+ and Il1rl2-/- mice at indicated time points. Data are representative of three independent 
experiments with 5 mice per group. All data presented as mean ± SEM (Multiple t tests - one per 




Figure 3.2 IL-36R-deficient results in diminished IL-22, IL-23, and IL-6 expression in the large 
intestine during C. rodentium infection.  
 
(A) Experimental schematic of intestinal bacterial infection by oral infected Il1rl2+/+ and Il1rl2-/- 
mice with 5-6x109 CFU of C. rodentium. (B and C) PCR array gene expression analyses from 
large intestine tissues isolated at indicated time points post infection of Il1rl2+/+ and Il1rl2-/- mice. 
(D and E) The top ten significantly expressed genes with highest upregulation were obtained from 
PCR array analysis between C. rodentium infected Il1rl2+/+ and Il1rl2-/- mice at day four post 
infection (D) and day 8 post infection (E). (F to H) The time course of (F) IL-22 (G) IL-23 (H) 
IL-6 protein expression from colonic tissues isolated from infected mice. Data are representative 
of two independent experiments with 4-5 mice per group. All data are presented as mean ± SEM. 




Figure 3.3 Early administration of exogenous IL-23 recuses Il1rl2-/- mice from C. rodentium 
infection.  
 
(A) Experimental schematic of C. rodentium infection by gastric gavage Il1rl2+/+ and Il1rl2-/- mice 
with 5-6x109 CFU of C. rodentium, in the presence or absence of IL-23. (B) Serial whole-body 
imaging of infected mice at indicated time points. Images are representative of 2 independent 
experiments with at least 5 mice/group. (C to E) (C) average body weight change; (D) survival 
rate; (E) bacterial shedding in feces of infected mice at indicated time points. (F and G) (F) The 
H&E staining and histology scoring (G) of colon sections from infected mice as in (A) are shown. 
(H) IL-22 protein expression in the colon at ten days post C. rodentium infection from Il1rl2+/+ 
and Il1rl2-/- mice. (I) Colonic lamina propria cells of C. rodentium infected mice at four days post 
infection were isolated analyzed by FACs for expression of intracellular IL-22 by Thy1+RORt+ 
gated cells. (J) FACs frequency data of Thy1+RORt+IL-22+ gated cells of infected mice generated 
as in (I). (K) Antimicrobial peptides mRNA expression in colon from infected mice at four days 
post infection. (L) Serial whole-body imaging of C. rodentium infected Il1rl2-/- mice in the 
presence or absence of IL-23 and neutralization antibodies, CD90 or CD4 at indicated. Images 
are representative of 2 independent experiments. (M to O) (M) survival rate; (N) average body 
weight changes; (O) bacterial shedding in feces of infected mice as in (L) at indicated time points. 
Data are representative of three independent experiments with 5 mice per group. All data presented 
as mean ± SEM (one-way ANOVA with Tukey’s multiple comparison test. *P < 0.5; **P < 0.05; 






















Figure 3.4 Administration of exogenous IL-6 during late phase of C. rodentium infection is 
associated with accelerate bacterial clearance and restoration of IL-22. 
 
(A) Experimental schematic of intestinal bacterial infection by gastric gavage Il1rl2+/+ and Il1rl2-
/- mice with 5-6x109 CFU of C. rodentium, in the presence or absence of recombinant IL-6 and/or 
CD4. (B) Serial whole-body imaging of infected mice at indicated time points. Images are 
representative of 2 independent experiments with at least 5 mice/group. (C to E) (C) survival rate; 
(D) average body weight changes; (E) bacterial shedding in feces of infected mice at indicated 
time points. (F and G) (F) The H&E staining, and (G) histology scoring of colon sections from 
infected mice as in (A) are shown. (H) IL-22 protein expression in colons from infected mice at 
ten days post infection. (I) Colonic lamina propria cells of C. rodentium infected mice as shown 
in (A) were isolated on day 10 post infection and analyzed by FACs for expression of intracellular 
IL-22 by TCR+CD4+ gated cells. (J) FACs frequency data from TCR+CD4+IL-22+ gated cells 
of C. rodentium infected mice generated base on (I). (K) Antimicrobial peptides mRNA expression 
in colon from infected mice at ten days post infection. Data are representative of three independent 
experiments with 5 mice per group. All data presented as mean ± SEM (one-way ANOVA with 




Figure 3.5 IL-36 signaling through an aryl hydrocarbon receptor induces IL-22 from CD4+ T cells 
is IL-6 -dependent.  
 
(A) DCs and CD4+T cells from spleen of WT mice were FACs sorted and were cultured either 
alone or co-cultured for 72h in the presence or absence of IL-36 Supernatant were analyzed for 
IL-22 by ELISA. (B) FACs sorted naïve CD4+T cells and DCs were co-cultured using indicated 
cell from Il1rl2+/+ and/or Il1rl2-/- mice with ± IL-36 for 72h IL-22 protein in supernatant was 
determined by ELISA. (C) IL-22 protein expression by FACs sorted co-culture DCs and naïve 
CD4+ T cells from ahr+/+ or ahr-/- mice in the presence of IL-36γ for 72h. (D) FACs sorted naïve 
CD4+T cells and DCs were co-cultured using indicated cell from ahr+/+ and/or ahr-/- mice with ± 
IL-36 for 72h IL-22 protein in supernatant was determined by ELISA. (E) FACs sorted DCs and 
CD4+ T cells from WT mice were co-cultured and stimulated with IL-36 and IL-6 antibody for 
72hrs. IL-22 protein was assessed by ELISA. (F and G) (F) BMDCs were generated from WT 
mice and cultured in the presence or absence of IL-36 for 24h, and IL-6 was assessed by ELISA. 
(F) Some cultures were pretreated with NFB inhibitor, or c-Rel inhibitor, or p50 inhibitor, or p65 
inhibitor or with vehicle control for 1hrs. (G) ChiP assays for p50, p65, and c-Rel binding to Il6 
promoter in BMDCs treated with ± IL-36 for 8h. Data are representative of three independent 
experiments with 4-5 replicates. All data presented as mean ± SEM (one-way ANOVA with 





Figure 3.6 IL-36 signaling induces IL-22 from CD4+ T cells is dependent on Notch ligands. 
 
(A) FACs sorted DCs and CD4+ T cells from wild-type mice were co-cultured and stimulated with 
IL-36 with the presence/absence of AHR or notch inhibitor for 72h. IL-22 protein expression 
were assessed by ELISA. (B to F) mRNA expression for Notch ligands from wild-type BMDCs 
stimulated with IL-36γ for 6h. (B) dll1 (C) dll2 (D) dll3 (E) jag1 (F) jag2. (G to I) DLL1 and 
DLL4 expression by sorted wild type DCs cultured with ± IL-36γ for 16h. (G) Representative 
FACs plots. (H) the frequencies of DLL1and (I) the frequencies of DLL4 among totals DCs. (J) 
FACs sorted DCs and naïve CD4+ T cells from wild-type mice were co-cultured and stimulated 
with IL-36 supplemented with indicated monoclonal antibodies for 72h. IL-22 protein were 
assessed by ELISA. Data are representative of three independent experiments with 4-5 replicates. 
All data presented as mean ± SEM (one-way ANOVA with Tukey’s multiple comparison test. *P 




Figure 3.7 IL-36γ and IL-36α, but not IL-36β, are induced in the large intestine during C. 
rodentium infection. 
 
 (A to C) Time course analysis Il1f6 (A), Il1f8 (B), and Il1f9 (B) mRNA expression in the large 
intestine from Il1rl2+/+ mice infected with 5-6x109 CFU C. rodentium. (D) Il1f9 mRNA 
expression from several large intestine immune cells at six days post-C. rodentium infection in 
Il1rl2+/+ mice. Data are representative of two independent experiments with 4-6 mice per group. 
(E) BMDCs were generated from Il1rl2+/+ mice and cultured with heat-killed C. rodentium for 6 
hours, and IL-36γ mRNA expression was assessed by real-time qPCR. Data are representative of 
two independent experiments with 3-4 replicates. All data presented as mean ± SEM (one-way 




Figure 3.8 IL-36 signaling is required to accelerate bacterial clearance but is not necessary for 
controlling systemic dissemination of bacteria.  
 
Four to six-week-old Il1rl2+/+ and Il1rl2-/- mice infected with bioluminescence C. rodentium (5-
6x109 CFU) by gastric gavage. (A) Bacterial clearance time of Il1rl2+/+ and Il1rl2-/- mice infected 
with bioluminescence C. rodentium evaluated by calculating bacterial shedding in feces of mice 
at indicated timepoint. (B) Bioluminescence images of several organs from Il1rl2+/+ and Il1rl2-/- 
mice ten days post infection with 5x109 CFU of C. rodentium. (C to F) Bacterial counts in colon 
and cecum (C), mesenteric lymph nodes (D), spleen (E), and liver (F) of Il1rl2+/+ and Il1rl2-/- mice 
infected with C. rodentium as in (B).  Data are representative of three two independent experiments 
with 4-5 mice per group. All data presented as mean ± SEM (one-way ANOVA with Tukey’s 





Figure 3.9 IL-36 signaling promotes innate immune cells infiltration during C. rodentium 
infection.  
 
(A) Colonic lamina propria cells of infected Il1rl2+/+ and Il1rl2-/- mice were isolated on the 
indicated days post infection and analyzed by flow cytometry for the infiltration of inflammatory 
neutrophil CD11b+Ly6G+ and monocytes CD11b+Ly6C+.  (B and C) FACs frequency data for 
lamina propria cells of infected Il1rl2+/+ and Il1rl2-/- mice generated as in (A). (D to G) Expression 
level neutrophil and monocytes chemoattractant (D) cxcl1 (E) cxcl2 (F) cxcl3 and (G) cxcl5 in 
large intestine from infected Il1rl2+/+ and Il1rl2-/- mice. Data are representative of two independent 
experiments with 5 mice per group. All data presented as mean ± SEM (one-way ANOVA with 
Tukey’s multiple comparison test. *P < 0.5; **P < 0.05; ***P < 0.001; ns, not significant).  
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Figure 3.10 Early administration of exogenous IL-23 to Il1rl2-/- mice infected C. rodentium 
induces modest IL-22 production from CD4+ T cells.  
 
(A) Colonic lamina propria cells of C. rodentium infected Il1rl2+/+ and Il1rl2-/- mice, in the 
presence/absence of IL-23 were isolated on day four post infection and analyzed by FACs for 
expression of intracellular IL-22 by TCRβ+CD4+ T gated cells. (B) FACs frequency data from LP 
cells of C. rodentium infected mice as shown in (A). Data are representative of three independent 
experiments with 5 mice per group. All data presented as mean ± SEM. (one-way ANOVA with 





Figure 3.11 IL-36 signaling drives IL-22 induction in CD4+ T cells by stimulating AHR.  
 
(A and B) FACs sorted naïve CD4+ T cells and DCs were co-cultured for 80 hours in the presence 
of IL-36γ and AHR inhibitor, CH-223191. (A) IL-22 protein, (B) IL-2 protein (B) in supernatants 
were assessed by ELISA. (C) FACs sorted naïve CD4+ T cells and DCs from tbx21+/+ and tbx21-
/- were co-cultured and stimulated with IL-36γ for 80 hours; in some-cultured AHR inhibitor, CH-
223191 were added. IL-22 protein expression in supernatant were assessed. Data are representative 
of three independent experiments with 4-5 replicates. All data presented as mean ± SEM (one-way 






Figure 3.12 IL-6 induces IL-22 production in CD4+ T cells via IL-6 
 
(A) FACs-sorted naïve CD4+ T cells and DCs were co-cultured for 80 hours in the presence of IL-
36γ and supplemented by indicated neutralizing antibodies for specific cytokines. IL-22 protein in 
supernatant was determined by ELISA. (B) FACs-sorted naïve CD4+ T cells and BMDCs were 
co-cultured using indicated cells from Il12b+/+ and Il12b-/- mice with presence of IL-36γ. IL-22 
protein in the supernatant was assessed by ELISA. Data are representative of three independent 
experiments with 4-5 replicates. All data presented as mean ± SEM (one-way ANOVA with 





Figure 3.13 IL-36 signaling via MyD88 and independent of NFB p50 and NFB c-rel subunit 
 
(A to C) BMDCs generated from wild-type, (A) myd88-/-, (B) p50-/- (B) or (C) c-rel-/- were 
stimulated with IL-36γ for 24 hours. IL-6 in supernatant were determined by ELISA. Data are 
representative of three independent experiments with 4-5 replicates. All data presented as mean ± 







Figure 3.14 IL-36 induces IL-22 secretion by T cells is independent of kynurenine pathway 
 
(A to D) FACs-sorted naïve CD4+ T cells and DCs were co-cultured and stimulated with IL-36γ 
for 80 hours. In some cultured, AHR inhibitor or 1-MT were added. (A) IL-22 (A), (A) IL-17A, 
(C) IFN-γ, and (D) IL-2 were assessed by ELISA. Data are representative of three independent 
experiments with 4-5 replicates. All data presented as mean ± SEM (one-way ANOVA with 





Figure 3.15 Proposed model of IL-36R/IL-22 axis for host protection against intestinal bacterial 
infection.  
 
C. rodentium infection stimulated inflammatory Ly6C+ monocytes migrated from bloodstream to 
the colon (1) to produced IL-36γ (2). IL-36γ binds to its receptor complex on DCs (3) and induces 
the production of IL-23 (4). In the early phase of infection, IL-23 binds to its receptor on 
ILC3/neutrophil (5) and stimulated the secretion of IL-22 (6). IL22 acts on IECs (7) to induce anti-
microbial peptide (8) to ward off bacteria from entering the intestine (9). In the late phase of 
infection, IL-36γ stimulates DCs to produce IL-6 (10a) or notch ligands DLL1/4 (10b). IL-6 and 
DLL1/4 bind to their respective receptors on CD4+ T cells (11a, 11b) and activate AHR. AHR 
activation lead differentiation of naïve CD4+ T cell into IL-22-producing T cells (12). IL-22 from 
T cell act on IEC (13) to induce AMPs 
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4 CHAPTER 4: INACTIVATION OF IL-36R SIGNALING AMILORATES CHRONIC 
INTESTINAL INFLAMMATION INDUCES BY HELICOBACTER HEPATICUS 
4.1 Introduction 
Inflammatory bowel disease (IBD), comprising ulcerative colitis and Crohn's disease, is a 
chronic inflammatory disorder of the gastrointestinal inflammation caused by abnormal immune 
responses to gut flora in the genetically susceptible host. Increased attachment of gut bacteria to 
the intestinal epithelium has been documented in IBD. The hallmark of active IBD is an abnormal 
mucosal infiltration by innate and adaptive immune cells and adaptive immune cells. Effector 
CD4+ T cells are critical in the defense against pathogens, whereas regulatory T are a critical in 
limiting the overactivity of CD4+ effector T cells [24]. IBD occurs when the balance between 
effector T cells and regulatory T cells is disturbed. Over the last few decades, the TH1 and TH17 
immune reaction and secretion of pro-inflammatory cytokines are implicated in the pathogenesis 
of IBD, especially CD.  
The relatively "newest" member of interleukin (IL)-1 cytokine superfamily, IL-36, has a 
crucial role in maintaining intestinal homeostasis. IL-36 agonists have been showed to be elevated 
in the inflamed gastrointestinal tissues in both human and animal experimental IBD models [43, 
45, 46, 55, 56]. In DSS induces chronic intestinal inflammation, IL-36α derived from CD163+, 
CD14+, and CD64+ macrophages regulate the production of pro-inflammatory cytokines and 
collagen type VI results in tissue fibrosis. Consequently, defective IL-36R signaling or preventive 
blockade of IL-36R signaling decreased intestinal inflammation and prevent fibrosis [2, 46].  
However, little information is currently available on the relative contribution of IL-36R 
signaling on T cell dependent chronic intestinal inflammation. Here, we used the model 
of Helicobacter hepaticus induced T cells dependent on chronic intestinal inflammation. We 
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observed that mice with inactivation of IL-36R signaling are protected from effector T cell driven 
chronic intestinal inflammation and displayed higher colonic regulatory T cell (Treg) with reduced 
TH1 and TH17 cells. 
4.2 Materials and Methods 
4.2.1 Mice 
Wild-type C57BL/6 (B6 WT) were obtained from Jackson Laboratories. IL-36R-/- mice 
(Il1rl2-/-) on the C57BL/6 background (backcrossed >9 generations) were originally provided by 
Amgen.   
4.2.2 H. hepaticus induces chronic colitis 
Hh NCI-Frederick isolate 1A (strain 51449) was grown on blood agar plates (Thermo 
Scientific) under microaerophilic conditions. Mice were fed 4 × 109 colony forming units (CFU) 
of H. hepaticus by oral gavage at day 0, 2 and 4. In addition, 0.5mg of an IL-10R blocking antibody 
clone 1B1.3A was administered as an intraperitoneal injection twice weekly starting at day 0 
of Hh infection.  
4.2.3 Real-time PCR 
Total RNA was isolated from mice colonic tissues using the Qiagen RNeasy Mini Kit 
according to manufacturer’s protocol. cDNA was generated with Superscript First Strand 
Synthesis kit according to manufacturer’s protocol. Q-PCR was performed with SYBR green 
(BioRad, CA) using a StepOnePlus PCR system (Applied Biosystem, CA) and gapdh were used 
to normalizes gene expression. 
4.2.4 Flow cytometry 
Fluorescence dye labeled antibodies (Abs) specific for TCRb, CD4, IFN-g, IL-17, FoxP3 
were purchased from Becton Dickinson (BD), Biolegend, eBioscience. Fc block (2.4G2) was 
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purchased from BioXcel. Dead cells were stained using the fixable Aqua dead cells staining kit 
(Invitrogen). Intracellular staining done after stimulation of cells with phorbol-12-myristate 13-
acetate and ionomycin (Sigma), and brefeldin A (eBioscience) for five hours. Stimulated cells 
were fix and permeabilized overnight and stained with antibodies specific for IFN-γ, IL-17 and 
FoxP3. 
4.2.5 Histology 
Colon tissues were fixed in 10% neutral formalin buffer. Paraffin embedding, sectioning 
and hematoxylin/eosin staining, and slide scanning were performed at Histowiz, Inc. (New York) 
4.2.6 Statically Analysis 
All statistical analyses were performed with GraphPad Prism software, version 8.0 
(Graphpad Software). ONE-way ANOVA and Tukey’s Multiple Comparison Test or Student’s t 
test were used to determine significance. *P < 0.05, **P < 0.01, ***P < 0.001; n.s.= not significant. 
4.3 Results and Discussion 
4.3.1 IL-36 cytokines are expressed during H. hepaticus induces intestinal inflammation.  
To determine the expression level of IL-36 agonists following H. hepaticus induces chronic 
intestinal inflammation, wild-type mice were infected with H. hepaticus strain ATCC 51449 and 
the expression of Il1f6 (IL-36α), IL-1f8 (IL-36), and IL-1f9 (IL-36γ) were assessed (Figure 
4.1A). Both IL-36α and IL-36γ mRNA levels were significantly induced in H. hepaticus infected 
large intestine at five weeks post-infection. No IL-36 mRNA was detected in H. hepaticus 
infected large intestine. (Figure 4.1 B) 
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4.3.2 Inactivation of IL-36R signaling in vivo ameliorates T cell driven intestinal 
inflammation. 
Previous studies have shown IL-36R signaling induced TH1 and TH17 cell differentiation 
in vitro [66, 67]; thus, we explored the role of the IL-36R signaling in T cell-dependent intestinal 
inflammation induced by H. hepaticus. H. hepaticus induced intestinal inflammation have both 
been described as Th1-like because inflammatory cells produce IFN-γ. We used mice deficient of 
IL-36R (Il1rl2-/-) to assess the contribution of IL-36R signaling in driving intestinal inflammation 
in this model. In responses to H. hepaticus infection, Il1rl2-/- mice experienced normal body weight 
gains and have less lipocalin-2 (lcn-2) which is a marker for inflammation in intestinal 
inflammation, and less colitis score (Figure 4.2A-C).  
Next, we determined the contribution of IL-36R signaling mediated regulation of effector 
T cell and regulatory T cell in vivo during intestinal inflammation. Following the infection of H. 
hepaticus, Il1rl2-/- mice exhibited significantly reduction in IFN-γ, IL-17A production by colonic 
T cells when compared that of mice. Moreover, the frequency of CD4+FoxP3+ regulatory T cell 
was significantly elevated in Il1rl2-/- mice (Figure 4.3 A and B). In addition, altered in IL-36R 
signaling pathway also resulted in decreased expression of proinflammatory genes including IL-
12, IL-23, IL-6 in both colon and caecum infected mice (Figure 4.4 A and B). 
T cells are one of the key initiators in the IBD. CD4+ T cells are enriched in the tissue from 
IBD patients with CD and UC, and blockade T cell trafficking molecules or depletion of CD4+ T 
cell is, in some cases, helpful to treating patients with IBD. In these studies, CD4+ T cell-depleting 
and blocking antibodies caused remission from the disease in several CD, and UC patients 
examined, suggesting a role of CD4+ T cells in propagating disease [2, 7, 24]. Numerous studies 
link chronic intestinal inflammation in IBD patients with increased levels of IL-36 cytokines [45, 
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46]. However, there is a lack of preclinical research into the role of IL-36 cytokines in promoting 
T cells dependent chronic intestinal inflammation. Here, using a bacterial driven T cell dependent 
intestinal inflammation, we dissected the role of IL-36R in chronic intestinal inflammation. The 
chronic intestinal inflammation develops in H. hepaticus-infected mice is associated with the 
elevation of IL-12, IL-23, and TH1 response to the bacterium. In this model, mice lack IL-36R 
signaling exhibited less proinflammatory cytokines expression, increased Treg, and diminished 
TH1, and TH17 CD4+ T cells resulted in significantly ameliorated intestinal inflammation. These 
data highlight the contribution of IL-36R in T cell driven chronic intestinal inflammation in mice 
and marked IL-36/IL-36R axis as an attractive therapeutic target to treat IBD.  
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Figure 4.1 IL-36α and IL-36γ mRNA are expressed during H. hepaticus induces intestinal 
inflammation. 
(A) Experimental schematic of intestinal bacterial infection by gastric gavage mice with H. 
hepaticus. (B) IL-36α, IL-36β, and IL-36γ mRNA expression in colonic tissues of wild-type 
mice infected H. hepaticus at 35 days post infection. 
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Figure 4.2 Inactivation of IL-36R signaling ameliorates chronic intestinal inflammation induces 
by H. hepaticus. 
Four to six-week-old Il1rl2+/+ and Il1rl2-/- mice infected with H. hepaticus by gastric gavage. (A) 
average body weight change. (B) average lcn-2 in mice feces at indicated time point. (C and D) 






Figure 4.3 Inactivation of IL-36R signaling enhance TH1/TH17 and inhibit FoxP3 differentiation. 
 
Four to six-week-old Il1rl2+/+ and Il1rl2-/- mice infected with H. hepaticus by gastric gavage. (A 
and B) FACs plot and FACs frequency data of colonic lamina propria cells of H. hepaticus 
infected mice at 35 days post infection were isolated analyzed by FACs expression of intracellular 





Figure 4.4 IL-36R signaling modulates the production of cytokines in mice infected with H. 
hepaticus. 
 
mRNA expression of proinflammatory cytokines from (A) colon (B) caecum of mice infected 
with H. hepaticus. 
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5 CHAPTER 5: CONCLUSION AND FUTURE STUDIES 
IL-36 cytokines are members of the IL-1 superfamily, although these cytokines were 
discovered almost twenty years ago, their functions remain enigmatic within the field of IBD. 
Recent work from our lab, and others, has unraveled the significant and complex contributions of 
the IL-36R signaling in mucosal immune responses during intestinal inflammation. We reported 
that IL-36 cytokines are expressed in multiple models of murine intestinal inflammation and during 
human IBD. We have shown that IL-36 ligands, especially IL-36γ, are secreted by Ly6C+ 
inflammatory monocytes in response to bacterial translocation caused by intestinal barrier damage, 
in mice. Like other members in IL-1 superfamily, IL-36 cytokines have a dichotomous role in 
intestinal inflammation (Figure 5.1). In the context of acute intestinal inflammation, several groups 
and we have observed Il1rl2-/- mice have reduced disease severity in the damage phase and 
correlated with a decrease of innate inflammatory cells such as neutrophil, monocytes, and 
macrophages. 
Interestingly, in the healing phase of acute intestinal injury, Il1rl2-/- mice exhibited 
defective recovery and impaired wound healing from DSS-induced damage. IL-36 mediated 
mucosal healing occurs via two mechanisms: (1) Il-36 induces the expression of IL-23/IL-22 and 
antimicrobial peptides. (2) Il-36 induces the proliferation of intestinal epithelial cells and activates 
fibroblasts. Upon tissue injury in the colon, IL-36α and IL-36γ are released from inflammatory 
macrophage and intestinal epithelial cells. Subsequently, these IL-36 ligands bind to IL-36R 
complex on target cells, including DCs, colonic fibroblasts, and intestinal epithelial cells (IECs); 
thereby, initiating effector mechanism that stimulates resolution of intestinal damage. IL-36 binds 
to its receptors on DCs and signals through MyD88 protein adaptor which activates NFB, c-rel, 
and p50 subunits which induce the expression of IL-23. Following the secretion of IL-23, 
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numerous cell types in the colon express IL-23R and can produce of IL-22. IL-22 then stimulates 
the restitution of IEC and the generation of antimicrobial peptides. Another mechanism of mucosal 
healing that is dependent on IL-36R signaling is IL-36 ligand activation of IL-36R+ colonic 
fibroblasts which induce expression of granulocyte-macrophage-stimulating factor (GM-CSF) and 
IL-6. Both GM-CSF and IL-6 are essential in the restoration of epithelial integrity after mucosal 
damages. Moreover, in vivo treatment with IL-36R ligands or IL-23 significantly accelerated 
mucosal healing. We have also demonstrated the importance of IL-36R signaling in host protection 
against intestinal bacterial infection. In the context of bacterial-induced intestinal inflammation, 
IL-36R deficiency resulted in reduced host ability to control enteropathogenic bacteria C. 
rodentium infection. This defective phenotype of Il1rl2-/- mice is associated with a decrease in 
recruitment of innate inflammatory cells and proinflammation cytokines, including IL-23, IL-6, 
and IL-22.  
Figure 5.1 The dichotomous roles of IL-36R signaling in intestinal inflammation 
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In contrast to acute and bacterial-induced intestinal inflammation, IL-36R signaling is 
pathogenic in chronic intestinal inflammation. We reported in the oxazolone and H. 
hepaticus models of colitis, signaling through the IL-36R complex inhibits Foxp3+ regulatory T 
cell (Treg) expansion and upregulates the differentiation of naïve CD4
+ T cells into TH1, TH17, and 
TH9 effector T cells. Mice with inactivated IL-36R are protected from effector T cell driven 
intestinal inflammation and display higher colonic Treg cells and reduced TH1/TH17/TH9 cells. We 
also investigated the impact of IL-36R signaling in the T cell transfer model of chronic intestinal 
inflammation. Naïve T cells (CD4+CD45RBhigh) were isolated from Il1rl2+/+ and Il1rl2-/- mice 
and transferred to recipients that lack T and B cells. In this model, rag1-/- mice that received IL-
36R-deficient CD45RBhigh cells exhibited moderate weight loss and colonic inflammation when 
compared to rag1-/-mice received IL-36R-deficient CD45RBhi cells. Recently published by 
Scheibe et al., revealed that tissue isolated from patients with IBD express a higher level of IL-
36α and collagens than healthy patients. In additional chronic intestinal inflammation models, 
including DSS and TNBS, IL-36α derived from CD163+, CD14+, and CD64+ macrophages govern 
the production of proinflammatory cytokines and collagen type VI resulting in tissue fibrosis. 
Administration of IL-36R agonist ligands led to an increase in the number of α-smooth muscle 
actin-positive cells. Treatment of mice with antibody-mediated inhibition of IL-36R reversed the 
established intestinal fibrosis and ameliorated inflammation. Currently, clinical trials targeting IL-
36R signaling with neutralizing antibodies are ongoing with IBD’s patients. 
           Despite the use of inhibitory agents that target proinflammatory cytokines and immune cell 
trafficking molecules, many patients with IBD do not respond to therapy or show loss of clinical 
response over time. The experiments in the dissertation in combination with the results from other 
groups, has established that the IL-36/IL-36R axis has a role in inducing the protective function as 
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well as a role in pathogenic effector TH cell differentiation. Therefore, IL-36 may be an attractive 
target during active chronic intestinal inflammation. However, it should be noted that this may 
lead to potential side effects, such as the increased risk for infections and impairment in barrier 
repair. It would be interesting to further research if simultaneously blocking IL-36R signaling and 
delivering pro-healing factors, such as IL-22 or pro-antimicrobial factors, could circumvent the 
complications that might arise when the IL-36/IL-36R axis is blocked.  
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